

# CURRICULUM VITAE

NAME Jer-Tsong Hsieh, Ph.D.

TITLE AND AFFILIATION Professor  
The University of Texas  
Southwestern Medical Center  
Dallas, TX 75235

OFFICE ADDRESS The University of Texas  
Department of Urology,  
Southwestern Medical Center  
5323 Harry Hines Blvd.,  
Dallas, TX 75390-9110  
(214) 648-3988 (PHONE)  
(214) 648-8786 (FAX)  
JT.Hsieh@UTSouthwestern.edu (E-mail)

## EDUCATION AND POSTGRADUATE TRAINING

1978-1982	B. S.	Department of Plant Pathology, National Taiwan University
1982-1984	M. S.	Department of Microbiology and Immunology, National Yang-Ming Medical College
1984-1989	Ph. D.	Department of Human Cancer Biology, University of Wisconsin-Madison
1989-1991	Postdoctoral fellow	Department of Urology The University of Texas M.D. Anderson Cancer Center
1991-1993	Research Associate	Department of Urology The University of Texas M.D. Anderson Cancer Center

## ACADEMIC AND PROFESSIONAL APPOINTMENTS

1993-1995	Assistant Professor	Department of Urology The University of Texas M.D. Anderson Cancer Center
-----------	------------------------	---

1994-1995	Faculty Member	Graduate School of Biomedical Sciences The University of Texas-Houston
1996-2000	Assistant Professor	Department of Urology The University of Texas Southwestern Medical Center
1996-present	Faculty Member	Cell Regulation Program Southwestern Graduate School of Biomedical Sciences
2000-2006	Associate Professor (tenured)	Department of Urology The University of Texas Southwestern Medical Center
2005-present	Director	Jean H. and John T. Walter, Jr., Center for Research in Urologic Oncology The University of Texas Southwestern Medical Center
2007-present	Faculty Member	Cancer Biology Program Southwestern Graduate School of Biomedical Sciences
2007-present	Professor	Dr. John McConnell Distinguished Chair in Prostate Cancer Research The University of Texas Southwestern Medical Center
2010-present	Faculty Member	Bioengineering Program Southwestern Graduate School of Biomedical Sciences

#### EXTRAMURAL INVITED PRESENTATION

##### A. Internationally or Nationally

Department of Protein Structure, Amgen Inc., Host: Dr. Hsieng S. Lu, March 1, 1996.

Department of Urology, Case Western Reserve University, Cleveland, OH, Host: Dr. Susan Marengo, April 24-25, 1997.

Dept of Tumor Radiation Therapy, Liu Hua Qiao Hospital, Guangzhou, P.R. China, Host: Dr. Xiao-Huai Wang, May 27, 1997.

Dept of Medical Research, Liu Hua Qiao Hospital, Guangzhou, P.R. China, Host: Dr. Yue-Hua Jiang, May 28, 1997.

Tumor Hospital, Sun Yat-Sen University of Medical Sciences , Guangzhou, P.R. China, Host: Dr. De-sen Wan, June 3, 1997.

Dept of Surgery, Veterans General Hospital-Taipei, Taipei, Taiwan, R.O.C., Host: Dr. Kuang-Kuo Chen, June 5, 1997.

Dept of Urology, China Medical College Hospital, TaiChung, Taiwan, R.O.C., Host: Dr. Hsi-Chin Wu, June 10, 1997.

Dept of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, R.O.C., Host: Dr. Yeou-Ping Tsao, February 11, 1997.

Dept of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, R.O.C., Host: Dr. Ying-Ming Chen, February 12, 1997.

Annual AACR meeting, Philadelphia, Pennsylvania, Host: Dr. Matthew Ellis, April 13, 1999.

Dept of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, R.O.C., Host: Dr. Yeou-Ping Tsao, May 24, 1999.

Cancer Center, National Defense Medical Center, Taipei, Taiwan, R.O.C., Host: Dr. Show-Li Chen, May 25, 1999.

Dept of Microbiology, National Taiwan University, Taipei, Taiwan, R.O.C., Host: Dr. Pei-Jer Chen, May 26, 1999.

Dept of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, R.O.C., Host: Dr. Ming-Ji Fann, May 28 1999.

Dept of Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, Host: Frank M. Torti, June 25, 1999.

8th Prout Neck Prostate Cancer Conference, Prout Neck, Me, Host: Donald J. Tindall, October 21-24, 1999.

Winship Cancer Center, Emory University, Atlanta, GA, Host, XiangXi Xu, May 2, 2000.

Dept of Pathology, Wayne State University, Detroit, MI, Host: Dr. Yong Q. Chen, December 19, 2000.

Vancouver General Hospital, University of British Columbia, Vancouver, Canada, Host: Dr. Martein. E. Gleave, September 27-28, 2001.

Division of Urology, Taichung Veterans General Hospital, Taiwan, R.O.C., Host: Dr. Chi-Rei Yang, May 23, 2002.

The 7th Taiwan Joint Cancer Conference, Taichung, Taiwan, R.O.C., Host: Society of Gynecologic Oncology, May, 4-5, 2002.

Department of Urology, China Medical College Hospital, Taichung, Taiwan, R.O.C., Host: Dr. Hsi-Chin Wu, May 7, 2002.

Department of Obstetrics and Gynecology, Veterans General Hospital, Taipei, Taiwan, R.O.C., Host: Dr. Chiou-Chung Yuan, May 8, 2002.

Department of Public Health, National Yang-Ming Medical University, Taipei, Taiwan, R.O.C., Host: Dr. Ying-Ming Chen, May 8, 2002.

Department of Microbiology, National Taiwan University, Taipei, Taiwan, R.O.C., Host: Dr. Shin-Liang Doong,, May 9, 2002.

Department of Medical Technology, Chang Gung University, Tao-Yuan, Taiwan, R.O.C., Host: Dr. Ching-Ping Tseng, May 10, 2002.

Taiwan-US Urology Research Symposium, Taipei, Taiwan, R.O.C., Host: Taiwan Urologic Association, August 24-25, 2002.

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, R.O.C., Host: Dr. Song-Kun Shyue, August 26, 2002.

Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, R.O.C., Host: Dr. Joen-Rong Sheu, August, 30, 2002.

Department of Therapeutic Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, Host: Dr. Allen Gao, April 6, 2003.

Department of Pathology, University of Rochester, Rochester, New York, Host: Dr. Chawnshang Chang, April 7, 2003.

Department of Urology, Xi'an Jiaotong University, Xi'an, China, Host: Dr. Dalin He, October 3-10, 2003.

Society for Basic Urologic Research, San Francisco, California, US., Host: Dr. Natasha Kyprianou, May 5, 2004

The 29<sup>th</sup> FEBS Congress, Warsaw, Poland, Host: Dr. Liliana Konarska, June 26-July 1, 2004.

The 10<sup>th</sup> SCBA International Symposium, Beijing, China, Host: Dr. Leland Chung, July 18-23, 2004.

Department of Urology, New York University, New York, New York, Host: Dr. Xue-Ru Wu, August 27, 2004.

The 18<sup>th</sup> Congress ESUR, Athens, Greece, Host: Dr. Helmut Klocker, November 4-6, 2004.

Department of Urology, Johns Hopkins Medical School, Baltimore, MD, Host: Dr. Robert Getzenberg, July 25-26, 2005.

The Cancer Institute of New Jersey, New Brunswick, NJ, Host: Dr. Ronald A. Morton, October 5, 2005.

Department of Urology, MD Anderson Cancer Center, Houston, TX, Host: Dr. Colin P. Dinney, October 10, 2005.

Department of Urology, Emory University, Atlanta, GA, Host: Dr. Leland W.K. Chung, November 10-11, 2005.

Cancer Center, UC Davis, Sacramento, CA, Host: Christopher Evans, January 25-26, 2006.

Department of Urology, Huadong Hospital, Shanghai, China, Host: Dr. Weiqing Qian, October 19, 2006.

Xi'an International Forum in Urology, Xi'an, China, Host: Dr. Dalin He, October 20-22, 2006.

11th Prouts Neck Prostate Cancer Conference, Prouts Neck, Me, Host: Robert Getzenberg, November 2-5, 2006.

Department of Urology, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Hsi-Chin Wu, December 25, 2006.

Department of Pharmacology, National Yang-Ming Medical University, Taipei, Taiwan, R.O.C., Host: Dr. Yeu Su, December 29, 2006.

Duncan Cancer Center, Baylor College of Medicine, Houston, TX, Host: Dr. Seth P. Lerner, April 20, 2007.

12<sup>th</sup> Urologic Conference, Northwest China, Xi'an, China, Host: Dr. Dalin He, October 13-14, 2007.

Prostate Cancer Skeletal Metastasis Meeting, Stone Mountain, GA, Host: Bob Vessella, February 5-7, 2008.

University of Wisconsin Comprehensive Cancer Center, Madison, WI, Host: Douglas McNeel, April 3-4, 2008.

73rd Annual Meeting of the Eastern Section of Japanese Urological Association, Tokyo, Japan, Host: Eiji Higashihara, September 18-19, 2008.

2nd Xi'an International Forum in Urology, Xi'an, China, Host: Dr. Dalin He, October 24-25, 2008.

Institute of Biomedical Technology, Chang Gung University, Tao-Yuan, Taiwan, R.O.C., Host: Dr. Ching-Ping Tseng, October 31, 2008.

Society for Basic Urologic Research, Phoenix, Arizona, US., Host: Dr. Shuk-Mei, Ho, November 20-23, 2008.

Cancer Center, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Chia-Lin Hsieh, February 20, 2009.

Global Collaboration on Urologic Research, Xi'an, China, Host: Dr. Dalin He, October 16-18, 2009.

National Health Research Institute, Taiwan, R.O.C., Host: Dr. Shuang-En Chuang, December 21, 2009.

Department of Urology, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Hsi-Chin Wu, December 22, 2009.

Basic Research in Urology Cancer Conference, Taichung Veterans General Hospital, Taiwan, R.O.C., Host: Dr. Chi-Rei Yang, December 26, 2009.

Institute of Biomedical Technology, Chang Gung University, Tao-Yuan, Taiwan, R.O.C., Host: Dr. Ching-Ping Tseng, December 29, 2009.

Department of Pathology, School of Medicine, Yale University, Host: Dr. Min Wang, February 25, 2010.

Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C., Host: Dr. Chi-Huei Wang, September 2, 2010.

Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Tainan, Taiwan, R.O.C., Host: Dr. Tzu-Fen Fu, September 8, 2010.

Chinese Urology Association, 17<sup>th</sup> annual meeting, Xi'an, China, Host: Dr. Yah Nan Yanqun, October 14-17, 2010.

Department of Life Science, National Normal University, Taipei, Taiwan, R.O.C., Host: Dr. Jocelyn Lai, October 21, 2010.

Department of Urology, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Hsi-Chin Wu, March 31, 2011.

Department of Structural and Cell Biology, Tulane University, Host: Dr. Dong Yang, April 27, 2011.

Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C., Host: Dr. Chi-Huei Wang, August 22, 2011.

Department of Microbiology and Immunology, National Yang-Ming Medical University, Taipei, Taiwan, R.O.C., Host: Dr. Yi-Ming Chen, September 5, 2011.

Department of Medical Research, Liu Hua Qiao Hospital, Guangzhou, P.R. China, Host: Dr. Jie Wang, October 14, 2011.

Department of Radiology, Fudan University, Shanghai, P.R. China, Host: Dr. Zhaolu Kong, October 17, 2011.

Winship Cancer Institute, Emory University, Host: Dr. Dong Jin-Tang, January 16, 2012.

Department of Urology, National Cheng Kung University, Tainan, Taiwan, R.O.C., Host: Dr. Wen-Horng Yang, August 31, 2012.

Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C., Host: Dr. Bing-Hung Chen, August 31, 2012.

Prostate Cancer Symposium, South Section-Taiwan Urology Association, Tainan, Taiwan, R.O.C., Host: Dr. Tsai, Tzong-Shin, September 1, 2012.

Department of Urology, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Chi-Rei Yang, September 10, 2012.

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, R.O.C., Host: Dr. Jeffrey Yen, September 13, 2012.

Department of Microbiology, National Taiwan University, Taipei, Taiwan, R.O.C., Host: Dr. Shin-Liang Doong, September 14, 2012.

Center of Genetics Medicine, School of Medicine, Northwestern University, Host: Jindan Yu, September 27, 2012.

5th Xi'an International Forum in Urology, Xi'an, China, Host: Dr. Dalin He, October 13-14, 2012.

International Forum on Recent Advances in Uro-Oncology, Los Angeles, CA, Host: Dr. Leland Chung, May 2-3, 2013.

University Lecture, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Allen Yu, September 13, 2013.

Department of Urology, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C., Host: Dr. Wen-Zeng Wu, September 16, 2013.

Department of Medicine, China Medical University, Taichung, Taiwan, R.O.C., Host: Dr. Chih-Ho Lai, March 14, 2014.

7<sup>th</sup> International Clusterin meeting, Universite De Versailles, st Quentin en Yvelines, France, Host: Dr. Gilles Chiocchia, June 12-14, 2014.

Symposium of Physiological Adaptation of Cancer, Taichung, Taiwan, R.O.C., Host: Dr. Jack Lin, August 30-31, 2014.

International Symposium for Contemporary Treatment Strategies of Prostate Cancer, Taipei, Taiwan, R.O.C., Host: Dr. Wei-Chung Yang, September 7, 2014.

Department of Biomedical Engineering, Pennsylvania State University, Host: Nanyin Zhang, September 24, 2014.

6<sup>th</sup> Xi'an International Forum of Urology, Xi'an, China, Host: Dr. Dalin He, October 17-18, 2014.

Society of Basic Urologic Research Fall meeting, Dallas, TX, Host: Allen Gao, November 13-16, 2014.

UT-NTU Joint Symposium - Frontier of Biological Sciences, Taipei, Taiwan, R.O.C., Host: Dr. Min-Liang Kuo, March 9, 2015.

## B. Locally or Regionally

Baylor Urology Symposium: "Advances and Controversies", Baylor Hospital, Dallas, TX, Host: Dr. Schnitzer, March 7-8, 1997.

Mini-symposium, *In vivo* Cancer, Cellular and Molecular Imaging Center, Dallas, TX, Host: Dr. Ralph P. Mason, July 9, 1999.

AUA Workshop: "Advances in BPH Research", Houston, TX, Host: Dr. John D. McConnell and Victor, K. Lin, July 30-August 1, 1999.

AUA Workshop: "Molecular Approaches to Therapy in Urologic Diseases", Houston, TX, Host: Dr. David M. Lubaroff and Michael O'Donnell, August 10-12, 2001.

Mini-symposium, *In vivo* Cancer, Cellular and Molecular Imaging Center, Dallas, TX, Host: Dr. Ralph P. Mason, August 31, 2001.

Department of Pharmacology, UT Southwestern medical Center, Dallas, TX, Host: Dr. Sophia Ran, September 19, 2001.

Medical Student Training Program (MSTP), UT Southwestern Medical Center, Dallas, TX, Host: Christopher Jones, February 26, 2002.

Technology seminar forum, CIE-DFW Chapel, Dallas, TX, Host: Dr. Victor, K. Lin, October 19, 2002.

Cell Imaging Program, Department of Radiology, UT Southwestern Medical Center, Dallas, TX, Host: Dr. Ralph Mason, October 19, 2005.

Cancer Biology Training program, Simmon Cancer Center, UT Southwestern Medical School, Dallas, TX, Host: Dr. David Boothman, December 20, 2007.

Small animal imaging Program, Department of Radiology, UT Southwestern Medical Center, Dallas, TX, Host: Dr. Dean Sherry, January 8, 2008.

Molecular Therapeutics of Cancer Program, Hamon Cancer Center, UT Southwestern Medical School, Dallas, TX, Host: Dr. John Minna, August 7, 2008.

Cell Imaging Program, Department of Radiology, UT Southwestern Medical Center, Dallas, TX, Host: Dr. Ralph Mason, February 10, 2009.

Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, TX, Host: Myoung Kim, April 1, 2009.

Department of Radiation Oncology, UT Southwestern Medical School, Dallas, TX, Host: Dr. Debabrata Saha, July 21, 2009.

Molecular Therapeutics of Cancer Program, Hamon Cancer Center, UT Southwestern Medical School, Dallas, TX, Host: Dr. John Minna, August 6, 2009.

Prostate Cancer Symposium, University of North Texas, Denton, TX, Host: Dr. Dennise Simmons, September 12, 2009.

Department of Bioengineering, University of Texas-Arlington, Arlington, TX, Host: Dr. Jian Yang, October 2, 2009.

Department of Physics, University of Texas-Arlington, Arlington, TX, Host: Dr. Wei Chen, July 22, 2010.

Department of Chemistry, University of Texas-Dallas, Richardson, TX, Host: Dr. Jie Zheng, March 9, 2012.

Texas Therapeutics Institute, University of Texas-Health Science Center, Houston TX, Host: Dr. Wenliang Li, April 19, 2013.

Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, Host: Dr. Jia Zhou, October 4, 2013.

## HONORS AND AWARDS

1978-1979                      President's Honors Award, National Taiwan University

1980-1981	President's Honors Award, National Taiwan University
1981-1982	President's Honors Award, National Taiwan University
1981-1982	Kou-Tai Foundation Fellowship
1983-1984	University Scholarship, National Yang-Ming Medical College
1984-1986	Government Scholarship from the Ministry of Education, Taiwan, R.O.C.
1986-1987	New Investigator Award (American Cancer Society)
1988	Cathay General Hospital Student Travel Fellowship
1991	Second Prize in The Society for Basic Urology Research (SBUR) Essay Contest
1991	Honorable Mention in M. D. Anderson Cancer Center Project Competition
1997	SBUR/Merck Young Investigator Award
2001	Visiting Professor, The Prostate Center at Vancouver General Hospital, BC, Canada
2003	Visiting Professor, Xi'an Jiaotong University, Xi'an, China
2006	Visiting Professor, Fudan University, Shanghai, China
2007	Visiting Professor, Xi'an Jiaotong University, Xi'an, China
2009	Visiting Professor, China Medical University, Taichung, Taiwan
2010-present	Adjunct Professor, China Medical University, Taichung, Taiwan
2011	Visiting Professor, Kaohsiung Medical University, Kaohsiung, Taiwan
2014	Adjunct Professor, Kaohsiung Medical University, Kaohsiung, Taiwan

#### SOCIETY MEMBERSHIPS

Phi Tau Phi Scholastic Honor Society  
 American Association for Cancer Research  
 American Urologic Association  
 Society of Chinese Bioscientists in America  
 Society of Basic Urologic Research  
 Chinese Society of Microbiology and Immunology

#### ACADEMIC SERVICE, ORGANIZATION OF LOCAL, NATIONAL OR INTERNATIONAL CONFERENCES

1. Chairman of Biomedical Research, 1993 Science, Engineering, and Technology Seminar (SETS), sponsored by American-Chinese Professionals, May 28-30,1993.
2. Chairman of Biomedical Research, 1994 Science, Engineering, and Technology Seminar (SETS), sponsored by American-Chinese Professionals, May 27-29,1994.
3. Coordinator of Science Section, 1995 Science, Engineering, and Technology Seminar (SETS), sponsored by American-Chinese Professionals, April 14-16,1995.
4. Organizer, Prostate Cancer Working Group, sponsored by Simmons Cancer Center, 1996-present.
5. Coordinator, North Texas Region Prostate Cancer Coalition, sponsored by UT Southwestern, UNT-Health Science Center, September 12, 2009.
6. Urologic Cancer tissue procurement subcommittee, UT Southwestern Tissue Resource, 2004-present.



7. Chairman, Prostate Cancer Symposium, UT Southwestern Simmons Cancer Center, October 28, 2013.
8. Organizer, Fall meeting of Society of Basic Urologic Research, November 13-16, 2014.
9. Co-Chairman, 5th Xi'an International Forum in Urology, Xi'an, China, October 17-18, 2014.
10. Co-Chairman, "Novel molecular mechanisms of prostate cancer progression" session, 15<sup>th</sup> SCBA International Symposium, Taipei, Taiwan, June 26-29, 2015.

GRANT REVIEW AND COMMITTEE SERVICE

1996-1999	Reviewer for Merit Award for Oncology Review Board of the Department of Veterans Affairs' Medical Research Services
1997	Member, NIH site visit team for "University of North Carolina Prostate Cancer Center", Sept. 29-Oct. 1, Chapel Hill, NC
1997-1998	Reviewer for Merit Award for Israel Science Foundation of The Israel Academy of Science and Humanities
2000	Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, July10-13, Viena, VA
2001	Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, May 20-23, Viena, VA
2001	Ad Hoc Reviewer, Association for International Cancer Research, UK
2001	Ad Hoc Reviewer, National Science Foundation
2002	Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, June 30-July 2, Baltimore, MD
2002	Ad Hoc Reviewer, National Science Foundation, Dutch Cancer Society
2003	Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, June11-13, Reston, VA
2004	Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, April18-20, Lansdowne, VA
2005	Panel Review Member, USAMRMC/CDMRP Breast Cancer Concept Award Research Program
2005	Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, April 7-9, Viena, VA
2005	Executive Committee, Society of Basic Urologic Research
2005	Ad-Hoc Member, NIH Hormone Regulation PO1 Cluster Study Section, May 18-19, Gaithersburg, MD
2005	Ad-Hoc Member, NIH Tumor microenvironment Study Section, June 6-7, Gaithersburg, MD
2005	Ad Hoc Reviewer, Association for International Cancer Research, UK
2005 to present	Tissue procurement and usage subcommittee, UT Southwestern Medical Center
2006	Ad Hoc Reviewer, Association for International Cancer Research, UK
2006	Ad Hoc Reviewer, Scottish Executive, Health department, UK
2008	Ad Hoc Reviewer, French National Research Fund, FR
2008	Ad Hoc Reviewer, North Carolina Biotechnology Center

2008 Ad Hoc Reviewer, National University of Singapore, Singapore

2008 Ad Hoc Reviewer, Association for International Cancer Research, UK

2009 Ad Hoc Panel Review Member, American Cancer Society, January 13-14, Atlanta, GA

2009 Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, March 20-27

2009 Ad Hoc Panel Review Member, American Cancer Society, June 16-17, Atlanta, GA

2009 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, June 29-30, Washington, DC

2009 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, October 28-29, Washington, DC

2010 Tumor Biochemistry and Endocrinology Review Panel Member, American Cancer Society, January 12-13, Atlanta, GA

2010 Panel Review Member, USAMRMC/CDMRP Prostate Cancer Research Program, April 1-6

2010 Tumor Biochemistry and Endocrinology Review Panel Member, American Cancer Society, June 24-25, Atlanta, GA

2010 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, July 1-2, Washington, DC

2011 Tumor Biochemistry and Endocrinology Review Panel Member, American Cancer Society, June 13-14, Atlanta, GA

2011 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, August 1-2, Washington, DC

2011 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, November 30-December 1, Washington, DC

2012 Tumor Biochemistry and Endocrinology Review Panel Member, American Cancer Society, January 10-11, Atlanta, GA

2012 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, March 21-22.

2012 Tumor Biochemistry and Endocrinology Review Panel Member, American Cancer Society, June 12-13, Atlanta, GA

2012 Ad Hoc Member, NIH Interdisciplinary Molecular Sciences and Training Study Section, July 24-25.

2012 Ad Hoc Member, Molecular Targets and Cancer Therapeutics (BMCT-C) Study Section, November 5, Washington, DC

2013 Tumor Biochemistry and Endocrinology Review Panel Member, American Cancer Society, January 15-16, Atlanta, GA

2013 Ad Hoc Member, NCI SPORE 1 (RPRB-M) Study Section, February 6-7, Washington, DC

2013 Ad Hoc Member, Molecular Targets and Cancer Therapeutics (BMCT-C) Study Section, February 25, Washington, DC

2013 Ad Hoc Member, NCI SPORE and RO1 (ZCA1 RPRB-0) Study Section, June 5-6, Washington, DC

- 2013 Ad Hoc Member, Drug development and delivery special emphasis panel, June 27-28, Washington, DC
- 2013 On-line Review Member of Molecular Biology and Genetics, USAMRMC/CDMRP Prostate Cancer Research Program, July 23-28.
- 2013 Ad Hoc Member, NCI's Provocative Questions RFA: R01 applications addressing Tumor Detection, Diagnosis, and Prognosis review panel, November 12-13, Washington, DC
- 2013 Review Member of Transformative Idea Award, USAMRMC/CDMRP Prostate Cancer Research Program, December 6, Baltimore, DC
- 2014 Ad Hoc Member, Molecular Targets and Cancer Therapeutics (BMCT-C) Study Section, February 24, Washington, DC
- 2014 U.S.-Israel Binational Science Foundation
- 2014 Ad Hoc Member, Omnibus Review "Targeted Delivery, Imaging, Biotechnology" Study Section, March 20-21, Washington, DC
- 2014 Ad Hoc Member, Molecular Targets and Cancer Therapeutics (BMCT-C) Study Section, June 30, Washington, DC
- 2014 Ad Hoc Member, Molecular Targets and Cancer Therapeutics (BMCT-C) Study Section, October 27, Sana Monica, CA
- 2014 Ad Hoc Member, NCI-I - Subcommittee I - Transition to Independence Study Section, November 4-5, Washington, DC
- 2015 Ad Hoc Member, Chemo/Dietary Prevention (CDP) Study Section, February 12-13, Washington, DC
- 2015 Ad Hoc Member, Molecular Targets and Cancer Therapeutics (BMCT-C) Study Section, February 23, Washington, DC
- 2015 Ad Hoc Member, RO3/R21 Omnibus Review Study Section, April 3, Washington, DC

#### EDITORSHIP AND EDITORIAL BOARD MEMBERSHIP

Ad Hoc reviewer for:

- 1995 to present Molecular Carcinogenesis
- 1996 to present Cancer Research
- 1996 to present Oncogene
- 1997 to present Molecular Endocrinology
- 1998 to present Molecular and Cellular Endocrinology
- 1998 to present Proceedings of National Academy of Science
- 1999 to present Clinical Cancer Research
- 1999 Human Gene Therapy
- 1999 to present Journal of Biologic Chemistry
- 1999 to present Endocrinology
- 2000 to present British Journal of Cancer
- 2000 to present Journal of Urology
- 2000 Genomics
- 2000 to present Gene
- 2001 to present Journal of Cellular and Molecular Biology
- 2002 Nature

2002	Gene Therapy
2002	Journal of Molecular Endocrinology
2003 to present	American Journal of Pathology
2003 to present	International Journal of Cancer
2003	Biochimica et Biophysica
2004	Journal of Cell Science
2005	Science
2005 to present	Molecular Cancer Therapy
2005 to present	Urology
2005 to present	Cancer Letter
2006	Journal of Neoplasia
2006	Breast Cancer Research and Treatment
2007	Genetic Vaccines and Therapy
2007 to present	Journal National Cancer Institute
2007	British Journal of Pharmacology
2007	Cancer Biology and Therapy
2007 to present	Endocrine-related Cancer
2007	Journal of Molecular Medicine
2007	Circulation Research
2008	FEBS Journal
2009	Cell Proliferation
2009 to present	Prostate
2010	Cancer Biology & Therapy
2010	Molecular Cancer
2010	British Journal of Cancer
2011 to present	PLOS One
2012	European Urology
2014	Tumor Biology
2014	Oncotarget

Editorial Board for:

2009 to present	Journal of Modern Urology
2014	Bladder

BIBLIOGRAPHY

A. Peer-reviewed publications

1. Hsieh, J.T., Ho, C.K. (1985) Cytostatic effect of interferon-g and monocyte against a human carcinoma cell line. Proceedings of National Science Council, Republic of China-Part B, Life Science, 9:50-55.
2. Hsieh, J.T., Ho, C.K., Pong, R.C., Chen, H.Y., Yung, C.H. (1985) Enhanced production of human interferon-g by the use of a combination of inducers-Phytohemagglutinin, Picibanil and tumor promoter agent. Proceedings of the National Science Council, Republic of China-Part B, Life Science, 9:311-313.

3. Hsieh, J.T., Verma, A.K. (1988) Involvement of protein kinase C in the transcriptional regulation of ornithine decarboxylase gene expression by 12-*O*-tetradecanoylphorbol-13-acetate in T24 human bladder carcinoma cells. *Arch. Biochem. Biophys.*, 262:326-336.
4. Hsieh, J.T., Verma, A.K. (1989) Lack of role of DNA methylation in tumor promoter 12-*O*-tetradecanoylphorbol-13-acetate-induced synthesis of ornithine decarboxylase messenger RNA in T24. *Cancer Res.*, 49:4251-4257.
5. Mehta, M.P., Kusbad, S.S., Fowler, J.F., Verma, A.K., Hsieh, J.T., Kinsella, T.J. (1990) <sup>90</sup>Y. B72.3 against pancreatic cancer: dosimetric and biological analysis. *Int. J. Radiat. Oncol., Biol., Phys.*, 99:627-631.
6. Hsieh, J.T., Denning, M.F., Heidel, S.M., Verma, A.K. (1990) Expression of human chromosome 2 ornithine decarboxylase gene in ornithine decarboxylase-deficient Chinese hamster ovary cell. *Cancer Res.*, 50:2239-2244.
7. Gleave, M.E., Hsieh, J.T., Gao, C., von Eschenbach, A.C., Chung, L.W.K. (1991) Acceleration of human prostate cancer growth *in vivo* by factors produced by prostate and bone fibroblasts. *Cancer Res.*, 51: 3753-3761.
8. Hsieh, J.T., Zhau, H.Y.E., Wang, X-H., Liew, C.C., Chung, L.W.K., (1992) Regulation of basal- and luminal cell-specific cytokeratin expression in rat accessory sex organs: evidence for a new class of androgen-repressed genes and an insight into their pairwise control. *J. Biol. Chem.*, 267:2303-2310.
9. Gleave, M.E., Hsieh, J.T., von Eschenbach, A.C., Chung, L. W.K. (1992) Prostate and bone fibroblasts induce human prostate cancer growth *in vivo*: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. *J. Urol.*, 147:1151-1159.
10. Gleave, M.E., Hsieh, J.T., Wu, H.C., Chung, L. W.K. (1992) Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. *Cancer Res.*, 52:1598-1605.
11. Chung, L.W.K., Li, W., Gleave, M.E., Hsieh, J.T., Wu, H.C., Sikes, R.A., Zhau, H.E., Bandyk, M., Logothetis, C., Rubin, J., von Eschenbach, A.C (1992) Human prostate cancer model : role of growth factors and extracellular matrices. *J. Cell Biochem., Supple.* 16H:99-105.
12. McDonnell, T.J., Troncoso, P., Brisbay, S.M., Logothetis, C., Chung, L.W.K., Hsieh, J.T., Tu, S-M., Campbell, M.L. (1992) Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. *Cancer Res.*, 52:6940-6944.

13. Hsieh J.T., Wu, H.C., Gleave, M.E., von Eschenbach. A.C., Chung, L. W.K. (1993) Autoregulation of prostate-specific antigen gene expression in human prostate carcinoma (LNCaP) subline. *Cancer Res.*, 53:2852-2857.
14. Gleave, M.E., Hsieh, J.T., Wu, H.C , Hong, S-J., Guthrie, P.D., Chung, L. W.K. (1993) Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. *Cancer Res.*, 53:5300-5307.
15. Hsieh, J.T., Lin S-H., (1994) Androgen regulation of cell adhesion molecule (CAM) gene expression in rat prostate during organ degeneration: C-CAM belongs to a new class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. *J. Biol. Chem.*, 269:3711-3716.
16. Wu, H-C., Hsieh, J.T., Gleave, M.E., Brown, N.M., Pathak, S., Chung, L.W.K., (1994) Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. *Intl. J. Cancer*, 57: 406-412.
17. Logothetis, C., Naseema, H, Hsieh, J.T. (1994) The clinical and biological study of androgen independent prostate cancer (AIPC). *Seminars in Oncology*, 21:620-629.
18. Wang, X, Hsieh, J.T. (1994) Androgen repression of cytokeratin gene expression during rat prostate differentiation: evidence for an epithelial stem cell-associated marker. *Chinese Med. Sci. J.*, 9:237-241.
19. Wang, X, Hsieh, J.T., Zhau, H.E. (1994) Cloning and characterization of a specific cytokeratin-8 cDNA from rat prostatic epithelium. *Acta Academiae Medicinae Sinicae*. 16: 1-7.
20. Wang, X, Hsieh, J.T. (1994) Localization and characterization of cytokeratin 8 mRNA expression in rat prostate epithelia. *J. Experimentalis Biology*, 27:447-455.
21. Hsieh, J.T., Luo, W., Song, W., Wang, Y., Kleinerman, D., Van, N.T., Lin S-H. (1995) Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. *Cancer Res.*, 55:190-197.
22. Kleinerman, D., Troncoso, P., Lin S-H., Pisters L.L., Sherwood E.R., Brooks T., von Eschenbach A.C., Hsieh, J.T. (1995) Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. *Cancer Res.*, 55:1215-1220.
23. Abdul, M., Hsieh, J.T., Logothetis, C., Naseema, H. (1995) Secretion of prostate-specific antigen (PSA) -suppressing activity by two human prostate carcinoma cell lines. *J. Urol. Oncology* 1:38-41.

24. Hsieh, J.T., Wu, H-C., Wang, Y., Song, W., Li, W., Finn, L., Logothetis, C. (1995) Evidence for the existence of an organ specific androgen-independent (AI) pathway of progression in patients with metastatic prostate cancer. *J. Urol. Oncology*, 1:67-72.
25. Kleinerman, D., Zhang, W.W., von Eschenbach, A.C., Lin S-H., Hsieh, J.T. (1995) Application of a tumor suppressor gene, C-CAM1, in androgen-independent prostate cancer therapy: a preclinical study. *Cancer Res.*, 55:2831-2836.
26. Luo, W., Liang, T.C., Li, J.M., Hsieh, J.T., Lin S-H. (1996) A universal tag for recombinant proteins. *Arch. Biochem. Biophys.*, 329: 215-220.
27. Liang, T.C., Luo, W., Hsieh, J.T., Lin S-H. (1996) Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxyl group. *Arch. Biochem. Biophys.*, 329:208-214.
28. Kleinerman, D., Diney C., Zhang, W.W., Lin S-H., Van, N.T., Hsieh, J.T. (1996) Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. *Cancer Res.*, 56: 3431-3435.
29. He, D., Mu, Z-M., Le, X., Hsieh, J.T., Pong, R., Chung, L.W.K., Chang, K-S. (1997) Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. *Cancer Res.*, 57:1868-1872.
30. Tseng, C-P., Ely, B., Pong, R-C., Li, Y., Hsieh, J.T.(1998) Regulation of the DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. *Endocrinology*, 139:3542-3553.
31. Li, Y., Pong, R.C., Hall, M.C., Sagalowsky A., Tseng, C-P., Wang, Z., Bergelson J., Hsieh, J.T. (1999) Loss of adenoviral receptor expression in human bladder cancer cells- A potential impact on the efficacy of gene therapy. *Cancer Res.*, 59:325-330.
32. Ruan, S., Okou, M.F., Pong, R.C., Andreeff, M, Hsieh, J.T., Zhang, W. (1999) Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-Bis(2-chloroethyl)-1-nitrosourea and cisplatin. *Clin. Cancer Res.*, 5:197-202.
33. Chen, Y.Q., Hsieh, J.T., Pong, R.C., Fang, B., Yao, F. (1999) Induction of Apoptosis and G2/M cell cycle arrest by DCC. *Oncogene*, 18:2747-2754.
34. Tsao, Y-P., Huang, S-J., Hsieh, J.T., Pong, R.C., Chang, J-L., Chen, S-L. (1999) Adenovirus-mediated p21(WAF1/Sdi1/Cip1) gene transfer induces apoptosis of human cervical cancer cell lines, *J. Virol.*, 73:4983-4990.
35. Hsieh, J.T., Early K, Pong, R.C., Wang, Y., Van, N.T., Lin S-H. (1999) Structural analysis of C-CAM1 molecule for its tumor suppression function in prostate cancer cells. *Prostate*, 41:31-38.

36. Tseng, C-P., Ely, B., Pong, R-C., Li, Y., Wang, Z., Zhou, J., Hsieh, J.T. (1999) The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity-an underlying mechanism of its tumor suppressive function. *J. Biol. Chem.*, 274:31981-31986.
37. Hall, M.C., Li, Y., Pong, R.C., Ely, B., Sagalowsky A., Hsieh, J.T. (2000) The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. *J. Urol.*, 163:1033-1038.
38. Leach, F.S., Hsieh, J.T., Molberg K., Saboorian M.H., McConnell, J.D., Sagalowsky A.I. (2000) Expression of the human mismatch repair gene, *hMSH2*: a potential marker for urothelial malignancy. *Cancer*, 88:2333-2341.
39. Liu, D-W., Tsao, Y-P., Hsieh, C-H., Hsieh, J.T., Kung, J.T., Chang, C-L., Huang, S-J., Chen, S-L. (2000) Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16E5 gene reduces tumor growth. *J. Virol.*, 74: 9083-9089.
40. Okegawa, T., Li, Y., Pong, R.C., Zhou, J., Bergelson J., Hsieh, J.T. (2000) The impact of coxsackie and adenovirus receptor on human prostate cancer gene therapy. *Cancer Res.*, 60: 5031-5036.
41. Leach, F.S., Velasco, A., Hsieh, J.T., Sagalowsky A.I., McConnell, J.D., (2000) The mismatch repair gene, *hMSH2*, is mutated in the prostate cancer cell line LNCaP. *J. Urol.*, 164:1830-1833.
42. Pisters, L.L., Wang, X.H., Chung, L.W.K., Hsieh, J.T. (2001) Differential expression of c-erb B2/neu, Epidermal growth factor receptor, cytokeratin 8, and the prostatic steroid binding protein gene in rat ventral prostate during postnatal development. *Prostate*, 47:164-171.
43. Zhou, J., Hsieh, J.T. (2001) The inhibitory role of DOC-2/DAB2 in growth factor receptors mediated signal cascade: DOC-2/DAB2-mediated inhibition of Erk phosphorylation via binding to Grb2. *J. Biol. Chem.*, 278:27793-27798.
44. Okegawa, T., Pong, R.C., Li, Y., Bergelson, J., Sagalowsky A.I. Hsieh, J.T. (2001) The mechanism of growth inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of CAR protein structure. *Cancer Res.*, 61: 6592-6600.
45. Tseng, C-P., Huang, C-H., Tseng, C-C., Hsieh, J.T., Lin M-H., Tseng, C-H (2001) Induction of Disabled-2 gene during megakaryocyte differentiation of K562 cells. *Biochem. Biophys. Res. Commun.*, 285:129-135.
46. Cohen, C.J., Pickles, R.J., Okegawa, T., Hsieh, J.T., Bergelson, J. (2001) The coxsackievirus and adenovirus receptor (CAR) is a transmembrane component of the tight junction. *Proc. Natl. Acad. Sci., USA.*, 98:15191-15196.



47. Li, Y., Okegawa, T., Lombardi, D. P., Frenkel, E.P., Hsieh, J.T. (2002) Enhanced transgene expression in androgen-independent prostate cancer gene therapy by chemotherapeutic agents. *J. Urol.*, 167:339-346.
48. Chen, H., Pong, R-C., Wang Z., Hsieh, J.T. (2002) Differential regulation of the human DAB2IP gene in normal and malignant prostatic epithelia: cloning and characterization. *Genomics*, 79:573-581.
49. Wang, Z., Tseng, C-P., Pong, R-C., Chen, H., McConnell, J.D., Navone, N., Hsieh, J.T. (2002) A Novel RasGTPase activating protein that interacts with DOC-2/DAB2: A downstream effector leading to the suppression of prostate cancer. *J. Biol. Chem.*, 277: 12622-12631.
50. Lin, J., Tang, H., Jin, X., Hsieh, J.T. (2002) p53 reduces Stat3 phosphorylation and induces apoptosis in human prostate cancer cells expressing constitutively active Stat3. *Oncogene*, 21:3082-3088.
51. Wang, C-H., Tsai, L-J., Tsao Y-P., Hsieh, J.T., Chien, W-W., Liao, C-L., Wang, H-W., Liu, H-S., Chen, S-L. (2002) Recombinant adenovirus encoding H-ras ribozyme is a potential cytotoxic agent in cancer cells regardless of containing wild-type or mutant H-ras gene. *Cancer research Biochem. Biophys. Res. Commun.*, 298:805-814.
52. Martinez, L.A., Rodriguez-Vargas, M.D., Yang, J., Olive, M., Vazquez, E.S., Hsieh, J.T., Logothetis, C.J., Navone, N.M. (2002) p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. *Carcinogenesis*, 23:1289-1296.
53. Chen, H, Toyooka, S., Gazdar, A.F., Hsieh, J.T. (2003) Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. *J. Biol. Chem.*, 278:3121-3130.
54. Zhou, J., Scholes, J., Hsieh, J.T. (2003) Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. *J. Biol. Chem.*, 276:6936-6941.
55. Zhang, R., He, X., Liu, W., Lu, M., Hsieh, J.T., Min, W. (2003) AIP1 mediated TNF-induced ASK1 activation by facilitating dissociation of ASK1 from inhibitor 14-3-3. *J. Clin. Invest.*, 11:1933-1943. ***Selected as a Highlight of the issue***
56. Lai Y.J., Pong, R.C., McConnell, J.D., Hsieh, J.T. (2003) A surrogate marker for predicting the virus sensitivity of urogenital cancer cells during adenovirus-based gene therapy. *Biotechniques*, 35:186-194.
57. Padar, A., Sathyanarayana, U.G., Suzuki, M., Maruyama, R., Hsieh, J.T., Frenkel, E.P., Gazdar, A.F. (2003) Inactivation of Cyclin D2 gene in prostate cancers by aberrant promoter methylation. *Clin. Cancer Res.*, 9:4730-4734.

58. Pong, R.C., Lai Y.J., Chen, H., Okegawa, T., Frenkel, E.P., Sagalowsky, A., Hsieh, J.T. (2003) Epigenetic control of Coxsackie and Adenovirus Receptor (CAR) gene in human urogenital cancer cells. *Cancer Res.*, 63:8680-8686.
59. Sathyanarayana, U.G., Padar, A., Suzuki, M., Maruyama, R., Shigematsu, H., Hsieh, J.T., Frenkel, E.P., Gazdar, A.F. (2003) Aberrant promoter methylation of laminin-5 encoding genes in prostate cancers and its relationship to clinicopathological features. *Clin. Cancer Res.*, 9:6395-6400.
60. Dote, H., Toyooka, S., Tsukuda, K., Yano, M., Ouchida, M., Doihara, H., Chen, H., Hsieh, J.T., Gazdar, A.F., Shimizu, N. (2004) Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. *Clin. Cancer Res.*, 10:2082-2089.
61. Huang, C.L., Cheng, J.C., Liao, C.H., Stern, A., Hsieh, J.T., Wang, C.H., Hsu, H.L., Tseng, C.P. (2004) Disabled-2 is a negative regulator of integrin  $\alpha$ IIb $\beta$ 3-mediated fibronogen adhesion and cell signaling. *J. Biol. Chem.*, 279:4279-42289.
62. Chen, H, Tu, S., Hsieh, J.T. (2005) Down regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. *J. Biol. Chem.*, 280:22437-22444.
63. Zhou, J., Tu, S., Hernandez, G., Scholes, J., Chen, H., Tseng, C.P., Hsieh, J.T. (2005) Synergistic induction of DOC-2/DAB2 gene expression in transitional carcinoma cells in the presence of GATA6 and histone deacetylase inhibitor. *Cancer Res.*, 65: 6089-6096.
64. Okegawa, T., Nutahara, K., Pong, R.C., Higashihara, E., Hsieh, J.T. (2005) Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. *J. Urol.*, 174:747-752.
65. Zhou, J., Hernandez, G., Tu, S., Huang, C.L., Tseng, C.P., Hsieh, J.T. (2005) The mechanism of antiandrogen effect of DOC-2/DAB2 on androgen receptor-mediated cell growth in androgen independent prostate cancer. *Cancer Res.*, 65:9906-9913.
66. Svatek, R., Herman, M.P., Lotan, Y., Casella, R., Lindberg, G., Hsieh, J.T., Sagalowsky, A., Shariat S.F. (2006) Soluble FAS- a promising novel urinary marker for the detection of recurrent bladder transitional cell carcinoma. *Cancer*, 106:1701-1707.
67. Lotan, Y., Stanfield, J., Cho, L.C., Sherwood, J.B., Abdel-Aziz, K.F., Chang, C.F, Forster, K., Kabbani, W., Hsieh, J.T, Choy, H., Timmerman, R. (2006) Efficacy of Cyberknife<sup>®</sup> stereotactic radiosurgical treatment for localized prostate cancer: a murine model. *J. Urol.*, 175:1932-1936.
68. Chen, H, Karam. J.A., Schultz, R., Zhang, Z., Ducan, C., Hsieh, J.T. (2006) Cloning of *mDAB2IP* gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region. *DNA and Cell Biol.*, 25: 232-245. ***Selected as a Cover Page***

69. Walsh, L., Stanfield, J., Cho, L.C., Chang, C.H., Forster, K., Kabbani, W., Cadeddu, J.A., Hsieh, J.T., Choy, H., Timmerman, R., Lotan, Y. (2006) Efficacy of ablative high dose per fraction radiation for implanted human renal cell cancer in a nude mouse model. *Euro. Urology*, 50:795-800.
70. Melquist, J.J., Kacka, M., Li, Y., Malaeb, B., Elmore, J., Baseman, A.G., Hsieh, J.T., Koeneman, K.S. (2006) Conditionally replicating adenovirus-mediated gene therapy in bladder cancer, an orthotopic *in vivo* model. *Urologic Oncol.*, 24:362-371.
71. Shen, S.S., Smith, C.L. Hsieh, J.T., Yu, J., Kim, I. Y., Jian, W., Sonpavde, G., Ayala, G.E., Younes, M., Lerner, S.P. (2006) Expression of estrogen receptor a and b in bladder cancer cell lines and human bladder tumor tissue. *Cancer*, 106:2610-2616.
72. Pong, R.C., Roark, R., Ou, J., Fan, J., Stanfield, J., Frenkel, E., Sagalowsky, A., Hsieh, J.T. (2006) Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. *Cancer Res.*, 66:8822-8828.
73. Zhou, J., Fan, J., Hsieh, J.T. (2006) Inhibition of mitogens-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle. *Cancer Res.*, 66:8954-8958.
74. Huang, C.L., Cheng, J.C., Stern, A., Hsieh, J.T., Liao, C-H., Tseng, C.P. (2006) Disabled-2 is a novel integrin  $\alpha$ IIb-binding protein that negatively regulate platelet-fibrinogen interaction and platelet aggregation. *J. Cell Sci.*, 119:4420-4430.
75. Höti, N., Chowdhury, W., Hsieh, J.T., Sacks, M.D., Lupoid, S.E., Rodriguez R. (2006) Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral cancer therapy. *Mol. Therapy*, 14:768-778.
76. Margulis, V., Shariat, S.F., Ashfaq, R., Thompson, M., Sagalowsky, A.I., Hsieh, J.T., Lotan, Y. (2007) Expression of Cyclooxygenase-2 in normal urothelium, superficial and advanced transitional cell carcinoma of urinary bladder. *J. Urol.*, 177:1163-1168.
77. Okegawa, T., Sayne, J.R., Nutahara, K., Pong, R.C., Saboorian, H., Kabbani, W., Higashihara, E., Hsieh, J.T. (2007) A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. *J. Urol.*, 177:1148-1156.
78. Karam, J.A., Fan, J., Stanfield, J., Richer, E., Benaim, E.A., Frenkel, E.P., Sagalowsky, A.I., Antich, P.P., Mason, R.P., Hsieh, J.T. (2007) The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-Azacytidine in human bladder cancer therapy. *Int. J. Cancer*, 120:1795-1802.
79. Huang, Y.C., Lee, C.M., Chen, M., Chung, M.Y., Chang, Y.H., Huang, J.S.W., Pan, C.C., Ho, M.T.D., Wu, T.T., Yang, S., Lin, M.W., Hsieh, J.T., Chen, Y.M.A. (2007) Haplotypes, loss of heterozygosity and expression levels of glycine *N*-methyltransferase in prostate cancer. *Clin. Cancer Res.*, 13:1412-1420.

80. Höti, N., Li, Y., Chen, C-L., Chowdhury, W., Johns, D.C., Xia, Q., Kabul, A., Hsieh, J.T., Berg, M.m Ketner, G., Lupold, S.E., Rodriguez R. (2007) Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenovirus. *Mol. Therapy*, 15:1495-1503.
81. Karam, J. A., Shariat, S.F., Huang, H-Y., Pong, R. C., Ashfaq, R., Shapiro, E., Lotan, Y., Sagalowsky, A.I., Hsieh, J.T. (2007) Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. *Clin. Cancer Res.*, 13:4400-4406.
82. Walsh, L., Miller, M.R., Anderson, J.K., Han, B., Hsieh, J.T., Lotan, Y., Cadeddu, J.A. (2007) In vitro assessment of the efficacy of thermal therapy in human renal cell carcinoma. *Urol.*, 70:380-384.
83. Zhang, Z., Stanfield, J., Frenkel, E.P., Hsieh, J.T. (2007) Histone deacetylase inhibitor (FK228) enhances the therapeutic efficacy of docetaxel in androgen independent prostate cancer. *Urol.*, 70:396-401.
84. Huang, H-Y., Shariat, S.F., Sun, T.T., Lepor, H., Shapiro, E., Hsieh, J.T., Ashfaq, R., Lotan, Y., Wu, R-X. (2007) Persistent uroplakin expression in advanced urothelial carcinomas: implications in clinical outcome. *Human Pathology*, 38:1703-1713.
85. Stern, J.M., Stanfield, J., Lotan, Y., Park, S., Hsieh, J.T., Cadeddu, J.A. (2007) The application of gold nanoshell assisted laser ablation on prostate cancer cell. *J. Endourol.*, 21:939-943.
86. Bartz, R., Zhou, J., Hsieh, J.T., Li, W., Anderson R.G.W., Liu, P. (2007) A potential autocrine/ paracrine effect of secreted caveolin-1 particle on prostate cancer growth. *Int. J. Cancer*, 122:520-525.
87. Stern, J.M., Stanfield, J., Kabbani, W., Hsieh, J.T., Cadeddu, J.A. (2008) Selective prostate cancer thermal ablation with laser activated gold nanoshells. *J. Urol.* 179:748-753.
88. Fan, J., Stanfield, J., Gao, Y., Karam, J.A., Frenkel, E.P., Sun, X., Hsieh, J.T. (2008) Effect of *trans*-2, 3-dimethoxycinnamoyl azide (DMCA) on enhancing anti-tumor activity of Romidepsin on human bladder cancer. *Clin. Cancer Res.*, 14:1200-1207.
89. Mullins, C., Lucia, M.S., Hayward, S.W., Lee, J.Y., Levitt, J.M., Lin, V.K., Hsieh, J.T., Liu, B.C., Chinnaiyan, A.M., Rubin, M.A., Slawin, K., Star, R.A., Getzenberg R.H.; MPSA Consortium (2008) A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. *J. Urol.*, 179:1243-1256.
90. Lim, J., Guo, Y., Rostollan, C.L., Stanfield, J., Hsieh, J.T., Sun, X., Simanek, E.E. (2008) The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. *Mol. Pharm.*, 5:540-547.
91. Di Maro, S., Pong, R.C., Hsieh, J.T., Ahn, J-M. (2008) Efficient Solid-Phase Synthesis of FK228 Analogues as Potent Antitumoral Agents. *J. Med. Chem.*, 51:6639-6641.

92. Zhou, Y-F., Gulaka , P., Zhou, J., Xiao, M., Xu, D., Hsieh, J.T., Kodibagkar, V., Sun X. (2008) Preparation and Evaluation of a Radioisotope-incorporated Iron Oxide Core/Au Shell Nanoplatform for Dual Modality Imaging. *J. Biomed. Nanotech* 4:1-9.
93. Liu, W., Hao, G., Long, M. A., Anthony, T., Hsieh, J.T., Sun, X. (2009) Impart Multivalency to a Bifunctional Chelator: A Scaffold Design for Targeted PET Imaging Probes. *Angewandte Chemie*, 48:7346-7349.
94. Xie, D., Gore, C., Zhou, J., Pong, R.C., Zhang, H., Yu, L., Min, W., Hsieh, J.T. (2009) DAB2IP/AIP1, a novel tumor suppressor, coordinates both PI3K-Akt and ASK1 pathways. *Proc. Natl. Acad. Sci., USA*, 106:19878-19883.
95. Li, Y., Kacka, M., Thompson. M., Hsieh, J.T., Koeneman, K.S. (2009) Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intra-osseous prostate cancer. *Urol. Oncol.* (In press), PMID: 19963408.
96. Li, Y., Malaeb, B.S., Li, Z., Thompson. M.G., Chen, Z., Corey D.R., Hsieh, J.T., Shay, J., Koeneman, K.S. (2010) Telomerase inhibition and cytolytic therapy in management of androgen independent osseous metastatic prostate cancer. *Prostate*, 70:616-629.
97. Xie, D., Liu, J., Gore, C., Yu, L., Pong, R.C., Hao, G., Long, M., Mason, R., Kabbani, W., Zhang, H., Chen, H., Sun, X., Boothman, D.A., Min, W., Hsieh, J.T. (2010) The role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. *Proc. Natl. Acad. Sci., USA*, 107:2485-2490. ***Selected as a Highlight of the issue***
98. Moro, L., Arbini, A.A., Hsieh, J.T., Simpson, E.R., Hajibeigi, A., Öz, K.O. (2010) Aromatase deficiency inhibits the permeability transition in mouse liver mitochondria. *Endocrinology*, 151:1643-1652.
99. Kong, Z., Xie, D., Boike, T., Raghavan, P., Burma, S., Chen, D.J., Habib, A.A., Chakraborty, A., Hsieh, J.T., Saha, D. (2010) Down-regulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. *Cancer Res.*, 70:2829-2839.
100. Dong, Y., Bey, E.A., Li, L-S., Kabbani, W., Yan, J., Xie, X-J., Hsieh, J.T., Gao, J., David A. Boothman, D.A. (2010) PARP-1 hyperactivation as a mechanism for radiosensitization in prostate cancer. *Cancer Res.*, 70:8088-8096.
101. Kong, Z., Xie, D., Boike, T., Raghavan, P., Burma, S., Chen, D.J., Chakraborty, A., Hsieh, J.T., Saha, D. (2010) Epothilone B confers radiation dose enhancement in DAB2IP gene knock down radio-resistant prostate cancer cells. *Int. J. Rad. Oncol., Biol. Phys.*, 78:1210-1218.

102. Rahimi, M., Wadajkar, A., Yousef, M., Hsieh, J.T., Kytai Nguyen, K. (2010) *In vitro* evaluation of novel polymer coated magnetic nanoparticles for controlled drug delivery. *Nanomedicine*, 6:672-680.
103. Hao, G., Zhou, J., Gao, Y., Long, M. A., Anthony, T., Stanfield, J., Hsieh, J.T., Sun, X. (2011) A cell permeable peptide analog as a potential specific PET imaging probe for prostate cancer detection. *Amino Acids*, 41:1093-1101.
104. Calvisi, D.F., Ladu, S., Conner, E.A., Seo, D., Hsieh, J.T., Factor, V.M., Thorgeirsson, S.S. (2011) Inactivation of *Ras* GTPase-Activating Proteins Promotes Unrestrained Activity of Wild-Type *Ras* in Human HCC. *J. Hepatology*, 54:311-319.
105. Karam, J.A., Huang, S., Fan, J., Stanfield, J., Schultz, R.A., Pong, R.C., Sun, X., Mason, R.P., Xie, J-X., Niu, G., Chen, X., Frenkel, E.P., Sagalowsky, A.I., Hsieh, J.T. (2011) Upregulation of TRAG3 gene, a surrogate marker for docetaxel resistance, associated with aggressive bladder cancer. *Int. J. Cancer*, 128:2823-2832.
106. Mairan, C.O., Yang, L., Pong, R.C., Gore, C., Shay, J.W., Kabbani, W., Hsieh, J.T., Raj, G.V. (2011) Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line. *Prostate*, 71:626-636.
107. Rao, S.M.N., Lin, V.K., Tata, U., Raj, R.V., Hsieh, J.T., Nguyen, K., Chiao, J-C. (2010) Demonstration of cancer cell migration using a novel microfluidic device. *Journal of Nanotechnology in Engineering and Medicine*, (In press).
108. Arbin, A.A., Greco, M., Yao, J.L., Bourne, P., Marra, E., Hsieh, J.T., di Sant'Agnes, P.A., Moro, L. (2011) Loss of BRCA2 protein expression is associated with elevated Skp2 levels in human prostate cancer. *Am. J. Pathol.*, 178:2367-2376.
109. Ford, J., Hajibeigi, A., Long, M., Hahner, L, Gore, C., Hsieh, J.T., Clegg, D., Zerwekh, J.E., Öz, K.O. (2011) GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. *J. Bone and Mineral Res.*, 26:298-307.
110. Hsieh, J.T., Zhou, J., Gore, C., Zimmern, P. (2011) R11: a novel cell permeable peptide as an intravesical delivery vehicle. *Brit. J. Urol.*, 108:1666-1671.
111. Vindrieux, D., Corre, L.L., Hsieh, J.T., Metivie, R., Escobar, P., Caicedo, A., Brigitte, M., Lazennec, G. (2011) Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancer. *Endocr. Relat. Cancer*, 18:311-21.
112. Lin, C.D., Lai, C.K., Lin, Y.H., Sing, Y.T., Hsieh, J.T., Chang, Y.C., Chen, K-C., Su, H.L., Wang, W.C., Lai, C.H. (2011) Cholesterol depletion reduces entry of *Campylobacter jejuni* cytolethal distending toxin and attenuates intoxication of host cells. *Infection and Immunity*. 79:3563-3575.

113. Zhang, Y-A., Maitra, A., Hsieh, J.T., Rudin, C.M., Karikari, C., Brekken, R.A., Sawyers, C., Wongvipat, J., Stastny, V., Gao, B., Wistuba, I., Frenkel, E., Minna, J.D., Gazdar, A.F. (2011) Frequent detection of infectious xenotropic murine leukemia virus (XMLV) strains in human cultures established from mouse xenografts. *Cancer Biology and Therapy*, 12:617-628.
114. Singh, A.N., Liu, W., Hao, G., Kumar, A., Gupta, A., Öz, O.K., Hsieh, J.T. Sun, X. (2011) Multivalent Bifunctional Chelator Scaffolds for <sup>68</sup>Ga-Based PET Imaging Probe Design: PET Signal Amplification *via* Multivalency. *Bioconjugate*, 22:1650-1662.
115. Mir, S.A., Best, S.L., McLeroy, S., Donnally, C.J., Gnade, B., Hsieh, J.T., Pearle, M.S., Cadeddu J.A. (2011) Novel stone–magnetizing microparticles: *in vitro* toxicity and biologic functionality analysis. *Endourol*, 25:1203-1207.
116. Vindrieux, D., Le Corre, L., Hsieh, J.T., Métivier, R., Escobar, P., Caicedo, A., Brigitte, M., Lazenne, G. (2011) Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancer. *Endocr Relat. Cancer*, 18:311-321.
117. Zhang, L., Jiao, M., Li, L., Wu, D., Wu, K., Li, X., Zhu, G., Dang, Q., Wang, X., Hsieh, J.T., He, D. (2012) Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. *J Cancer Res. Clin. Oncol.*, 138:675-686.
118. Zhou, J., Liu, W., Pong, R.C., Hao, G., Sun, X., Hsieh, J.T. (2012) Analysis of oligo-arginine cell permeable peptides uptake by prostate cells. *Amino Acids*, 42:1253-1260.
119. Zhou, J., Qin, L., Tien, J., Gao, L., Chen, X., Wang, F., Hsieh, J.T., Xu, J. (2012) Nkx3.1 functions as a “Para-transcription Factor” to regulate gene expression and cell proliferation in a non-cell-autonomous manner. *JBC*, 287:17248-17256.
120. Yang, L., Ravindranathan, P., Ramanan, M., Hammes, S., Hsieh, J.T., Raj, G.V. (2012) Central role for PELP1 in non-androgenic activation of the androgen receptor in prostate cancer. *Mol. Endo.*, 26:550-561.
121. Zhang, L.L., Li, L., Jiao, M., Wu, D., Wu, K., Li, X., Zhu, G., Yang, L., Wang, X., Hsieh, J.T., He, D. (2012) Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. *Cancer Letter*, 323:48-57.
122. Petty, A., Myshkin E., Qin, H., Guo, H., Miao, H., Tochtrop, G.P., Hsieh, J.T., Page, P., Liu, L., Lindner, D.J., Acharya, C., MacKerell, A.D., Ficker, E., Song, J., Wang, B. (2012) Doxazosin is a small molecule agonist for EphA2 receptor tyrosine kinase and inhibits cell migration *in vitro* and distal metastasis *in vivo*. *PLoS One*, 7:e42120.
123. Wu, K., Gore, C., Yang, L., Fazil, L., Gleave M., Pong, R.C., Xiao, G., Zhang, L.L., Yun, E.J., Tseng, S.F., Kapur, P., He, D., Hsieh, J.T. (2012) Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. *Mol. Endo.*, 26:1496-1507. ***Selected as a Cover page and Highlight of the issue***

124. Wu, K., Fan, J., Zhang, L., Ning, Z., Zeng, J., Zhou, J., Li, L., Chen, Y., Zhang, T., Wang, X., Hsieh, J.T., He, D. (2012) PI3K/Akt to GSK3 $\beta$ / $\beta$ -catenin signaling cascade Coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 Transcription. *Cell Signal.*, 24:2273-2282.
125. Yu, L., Tumati, V., Tseng, S.F., Hsu, F., Kim, D.N., Hong, D., Hsieh, J.T., Jacobs, C., Debabrata Saha D. (2012) DAB2IP regulates autophagy in prostate cancer in response to ionizing radiation and a DNA-PKcs inhibitor NU7441. *Neoplasia*, 14:1203-1212.
126. Wadajkar, A.S., Jyothi U. Menon, J.U., Tsai, Y.S., Gore, C., Dobin, T., Gandee, L., Kangasniemi, K., Takahashi, M., Ahn, J-M., Hsieh, J.T., Nguyen, K.T. (2013) Develop prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles. *Biomaterials*, 34:3618-3625.
127. Tumati, V., Mathur, S., Boike, T., Song, K., Hsieh, J.T., Zhao, D., Takahasi, M., Dobin, T., Gandee, L., Solberg, T., Habib, A., Saha, D. (2013) Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy. *Intl. J. Oncology*, 42:1613-1619.
128. Ro, S., Ma, H-Y., Park, C., Ortogero, N., Song, R., Hennig, G.W., Zheng, H., Lin, Y-M., Moro, L., Hsieh, J.T., Yan W (2013) The mitochondrial genome encodes abundant small noncoding RNAs. *Cell Res.*, 23:759-774.
129. Lai, C.K., Lu, Y.L., Hsieh, J.T., Tsai, S.C., Feng, C.L., Tsai, Y.S., Tsai, P.C., Su, H.L., Lin, Y.H., Lai, C.H. (2013) Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. *Nanomedicine*, 9:803-817.
130. Ravindranathan, P., Lee, T-K., Yang, L., Centenera M.M., Bulter, L., Tilley, W.D., Hsieh, J.T., Ahn, J-M., Raj, G.V. (2013) Targeting critical protein-protein interactions involved in androgen receptor nuclear translocation. *Nat. Commun.*, 4:9123.
131. Wu, K., Xie, D., Zou, Y., Zhang, T.T., Fazil, L., Gleave M., Pong, R., Xiao, G., Boothman, D., He, D., Hsieh, J.T. (2013) Mechanism of DAB2IP in chemo-resistance of prostate cancer cells. *Clin. Cancer Res.*, 19:4740-4749.
132. Wang, L., He, D., Zeng, J., Guan, Z., Dang, Q., Wang, X., Wang, J., Huang, L., Cao, P., Zhang, G., Hsieh, J.T., Fan, J. (2013) Raman spectroscopy, a potential tool in diagnosis and prognosis of castration-resistant prostate cancer. *J. Biomedical Optics*, 18:87001.
133. Hao, G., Kumar, A., Dobin, T., Oz, O., Hsieh, J.T., Sun, X. (2013) A multivalent approach of Imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. *Mol. Pharm.*, 10:2975-2985.
134. Patra, S., Kozura, B., Huang, A.Y., Enciso, A.E., Sun, X., Hsieh, J.T., Kao, C.L., Chen, H.T., Simanek, E.E. (2013) Dendrimers terminated with dichlorotriazine groups provide a route to compositional diversity. *Org. Lett* 15:3808-3011.



135. Chang, L-Y., Chou, R-H., Zeng, H-J., Hsieh, J.T., Yu, Y-L. (2013) Downregulation of DAB2IP promotes mesenchymal-to-neuroepithelial transition and neuronal differentiation of human mesenchymal stem cells. *PLoS One*, 8:e75884.
136. Hsu F.N., Chen, M.C., Lin, K.C., Lin, E., Chiang, M.C., Hsieh, J.T., Lin, H. (2013) Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells. *Am. J. Physiol.*, 305:E975-986.
137. Arbin, A., Guerra F., Greco, M., Marra, E., Gandee, L., Gandee, L., Xiao, G., Lotan, Y., Gasparre, G., Hsieh, J.T., Moro, L. (2013) Mitochondrial DNA mutations sensitize cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. *Oncogenesis*, 2:e82.
138. Wu, K., Xie, D., Liu, J., Tseng, S.F., Gore, C., Nig, Z., Sharifi, N., Fazil, L., Gleave M., Kapur, P., Xiao, G., Wang, M., Sun, X., ÖZ, O.K., Alexandrakis, G., Yang, C.R., Hsieh, C-L., Wu, H-S., He, D., Hsieh, J.T. (2014) The role of DAB2IP in androgen receptor activation during prostate cancer progression. *Oncogene*, 33:1954-1963.
139. Cai, H., Wu, J-S., Muzik, O., Hsieh, J.T., Lee, R.J., Peng, F. (2014) Reduced <sup>64</sup>Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. *J. Nucl. Med.*, 55:622-628.
140. Wang, S., Kollipara, R.K., Srivastava, N., Dobin, T., Kapur, P., Lotan, Y., Raj, G., Hsieh, J.T., Kittler R. (2014) Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. *Proc. Natl. Acad. Sci., USA.*, 111:4251-4256.
141. Wu, K., Ning, Z., Zhou, J., Wang, B., Fan, J., Zhu, J., Gao, Y., Wang, X., Hsieh, J.T., He, D. (2014) 2'-Hydroxyflavanone inhibits prostate tumor growth through inactivation of AKT/STAT3 signaling and induction of cell apoptosis. *Oncol. Rep.*, 32:131-138.
142. Zhang, T., Zhang, L., Zhang, T., Fan, J., Wu, K., Guan, Z., Wang, X., Li, L., Hsieh, J.T., He, D., Guo, P. (2014) Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PK<sub>CS</sub> In Vitro and In Vivo. *Radiat Res.*, 181:641-649.
143. Jacobs, C., Tumati, V., Kapur, P., Yan, J., Hong, D., Bhuiyan, M., Xie, X., Pistenmaa, D., Hsieh, J.T., Yu, L., Saha, D., Kim N. (2014) DOC-2/DAB2 Interaction Protein Status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy. *Int. J. Rad. Oncol., Biol. Phys.*, 89:729-735.
144. Xie, Z., Zhang, Y., Liu, L., Weng, H., Mason, R.P., Tang, L., Nguyen, K.T., Hsieh, J.T., Yang, J. (2014) Development of Intrinsically Photoluminescent and Photostable Polylactones. *Advanced Materials*, 26:4491-4496.
145. Zhou, J., Wu, K., Gao, D., Zhu, G., Wu, D., Wang, X., Chen, Y., Du, Y., Song, W., Ma, Z., Authement, C., Saha, D., Hsieh, J., He, D. (2014) Reciprocal regulation of hypoxia-

inducible factor 2 $\alpha$  and GLI1 expression associated with the radioresistance of renal cell carcinoma. *Int. J. Rad. Oncol., Biol. Phys.*, 90:942-951.

146. Lai, C-H., Chang, C-S., Liu, H-H., Tsai, Y-S., Hsu, F-M., Yu, Y-L., Lai, C-K., Gandee, L., Pong, R-C., Hsu, H.W., Yu, L., Saha, D., Hsieh, J.T. (2014) Sensitization of radio-resistant prostate cancer cells by a unique cytolethal distending toxin. *Oncotarget*, 5:5523-5534.
147. Tsai, Y.S., Chang, K-H., Wu, K., Tseng, S-F., Xie, D., Lai, C-H., Fazli, L., Gleave, M., Sun, H., Xiao, G., Gandee, L., Sharifi, N., Moro, L., Tzai, T-S., Hsieh, J.T. (2014) The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate tumorigenesis. *Oncotarget*, 5:6425-6436.
148. Ning, Z., Wu, K., Fan, J., Wang, B., Lv, C., Zhu, J., Wang, X., Hsieh, J.T., He, D. (2014) Aberrant expressions of  $\beta$ -catenin and ZEB1 in bladder cancer and their significance. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*. 30:1080-1083.
149. Yun, E-J., Baek, S.T., Tseng, S.F., Dobin, T., Zhang, L., Sun, H., Xie, D., Xiao, G., He, D., Kittler, R., Hsieh, J.T. (2014) DAB2IP represses CD117 gene transcription and its signaling cascade in regulating cancer stem cell. *Oncogene* (In press).
150. Gandee, L., Hsieh, J.T., Sperandio, V., Moreira, C., Lai, C.H., Zimmern, P. (2015) The efficacy of immediate versus delayed antibiotic administration on bacterial growth and biofilm production of selected strains of uropathogenic *Escherichia coli* and *Pseudomonas aeruginosa*. *Int. Braz. J. Urol.* 41:67-77.
151. Ilyas, A., Asghar, W., Ahmed, S., Lotan, Y., Hsieh, J.T., Kim, Y-T., Iqbal, S.M. (2014) Electrophysiological analysis of biopsy samples using elasticity as an inherent cell marker for cancer detection. *Analytic Methods* (In press).
152. Menon, J.U., Tumati, V., Hsieh, J.T., Nguyen, K.T., Saha, D. (2014) Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells. *Journal of Biomedical Materials Research: Part A* (In press).
153. Lai, C.K., Su, J.C., Lin, Y.H., Chang, C.S., Feng, C.L., Lin, H.J., Lin, C.J., Tseng, G.C., Liu, H.H., Hsieh, J.T., Su, H.L., Lai, C.H. (2015) Involvement of cholesterol in *Campylobacter jejuni* cytolethal distending toxin-induced pathogenesis. *Future Microbiol.*,10:489-501.
154. Amit, K., Hao, G., Li, L., Ramezani, S., Hsieh, J.T., Oz, O., Sun, X. (2015) Click-chemistry Strategy for Labeling Antibodies with Copper-64 via a Cross-bridged Tetraazamacrocyclic Chelator Scaffold. *Bioconjugate Chem.* (In press).
155. Zhang, T., Shen, Y., Chen, Y., Hsieh, J.T., Kong, Z. (2015) The ATM Inhibitor KU55933 Sensitizes Radio-resistant Bladder Cancer Cells with DAB2IP Gene Defect. *Int. J. Rad. Biol.* (In press).

156. Zhou, J., Wu, K., Luo, J., Yun, E-J., Kapur, P., Pong, R-C., Du, Y., Wang, B., Authement, C., Hernandez, E., Jichen Yang, J., Xiao, G., Cha, T-L., Wu, H-C., Wu, D., Margulis, V., Lotan, Y., Brugarolas, J., He, D., Hsieh J.T. (2015) DAB2IP loss confers resistance to targeted therapies in renal cancer by coordinately activating ERK and PI3K signaling pathways. *Clin. Cancer Res.* (submitted).
157. Rao, S.M.N., Jer-Tsong Hsieh, J.T., Lin, V.K., J. -C. Chiao J-C., (2015) *In Situ* immunocytochemical analysis of chemotaxis of prostate cancer cells using a microfluidic device. *Journal of Nanotechnology in Engineering and Medicine* (submitted).
158. Zhang, T., He, D., Wu, K., Sun, K., Guan, Z., Wang, X., Hsieh, J.T., Fan, J. (2015) The Therapeutic Effect of a Small Peptide Derived from p53 on Bladder Cancer. *EMBO Mol. Med.* (submitted).
159. Wei, J-H., Haddad, A., Wu, K., Zhao, H-W., Kapur, P., Zhang, Z-L., Zhao, L-Y., Chen, Z-H., Zhou, Y-Y., Zhou, J.C., Wang, B., Yu, Y-H., Cai, M-Y., Xie, D., Liao, B., Li, C-X., Li, P-X, Wang, Z-R., Zhou, F-J., Shi, L., Liu, Q-Z., Gao, Z-L., He, D., Chen, W., Hsieh, J.T., Li, Q-Z., Margulis, V., Luo, J-H. (2015) CpG methylation and clinical outcome in clear cell renal cell carcinoma: a genome-wide analysis and international validation study. *Nat. Comm.*(submitted).
160. Yun, E.J., Zhou, J., Lin, C-H., Hernandez, E., Fazli, L., Gleave, M., Hsieh, J.T. (2015) Targeting cancer stem cell in castration resistant prostate cancer. *Clin. Cancer Res.* (submitted).
161. Lo, U., Pong, R.C., Yang, D., Gandee, L., Zhou, J.C., Tseng, S-F., Hsieh, J.T. (2015) IFIT5 complex, a unique microRNA turnover machinery, leading to epithelial-to-mesenchymal transition in prostate cancer. *Nat. Comm.* (submitted)
162. Duan, L., Rai, G., Roggero, C., Zhang Q., Wei, Q., Ma, S-H., Santoyo, J., Martinez, E., Xiao, G., Raj, G., Jadhav, A., Simeonov, A., Maloney, D., Rizo, J., Hsieh, J.T., Liu Z-P. (2015) JMJD2 histone demethylase inhibitors block the growth of castration-resistant prostate tumors by suppressing the expression of BMYB-regulated cell cycle genes. *Cancer Res.* (submitted).

B. Invited review article, editorial comment, and book chapter

1. Verma, A.K., Hsieh, J.T., Pong, R.C. (1989) Mechanisms involved in ornithine decarboxylase induction by 12-*O*-tetradecanoylphorbol-13-acetate, a potent mouse skin tumor promoter and an activator of protein kinase C. In: *Progress in polyamine research* (Vincenzo Zappia ed.), Plenum Publishing Company, New York. pp 273-290.
2. Chung, L.W.K., Gleave, M.E., Hsieh, J.T., Hong, S-J., Zhau, H.Y.E. (1991) Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness. In *Cancer Survey* (L.M. Franks ed.), Cold Spring Harbor Laboratory Press, New York. pp 91-121.

3. Hsieh, J.T. (1993) Bone-derived growth factors in the promotion of osseous metastasis from prostate cancer. *Cancer Bulletin*, 45:442-447.
4. Gleave, M.E., Hsieh, J.T. (1997) Animal models in prostate cancer. *In Principle and Practice of Genitourinary Oncology* (D. Raghavan, H.I. Scher, S.A. Leibel, and P.H. Lange, ed), Lippincott-Raven Publisher, Philadelphia, pp 367-378.
5. Hsieh, J.T., Dinney, C.P.N., Chung, L.W.K. (2000) From Bench to Bedside: The Potential Role of Gene Therapy in the Treatment of Bladder Cancer. *In Urologic Clinics of North America* (Volume 27) Superficial Bladder Cancer: New Strategies in Diagnosis and Management (K.R. Laughlin ed.), pp103-113.
6. Hsieh, J.T. (2000) The role of Cell adhesion molecules in prostate development and carcinogenesis. *In Prostate Cancer in the 21st Century* (L.W.K. Chung, W.B. Isaacs, and J. Simmons ed), Humana Press, New Jersey, pp 207-218.
7. Koeneman, K.S., Hsieh, J.T. (2001) The prospect of gene therapy for prostate cancer: update on theory and status. *Current Opinion in Urol.*, 11:489-494.
8. Zhou, J., Scholes, J., Hsieh, J.T. (2001) Signal transduction targets in androgen independent prostate cancer. *Cancer and Metastasis Review*, 20:351-362.
9. Okegawa, T., Li, Y., Pong, R.C., Hsieh, J.T. (2002) Cell adhesion proteins as tumor suppressors. *J. Urol.*, 167:1836-1843.
10. Karam J., Mason, R., Koeneman, K., Antich, P.P., Benaim, E., Hsieh, J.T. (2003) Molecular imaging in prostate cancer. *J. Cell. Biochem.*, 90:473-483.
11. Okegawa, T., Pong, R.C., Li, Y., Hsieh, J.T. (2004) The role of cell adhesion molecule in cancer progression and its application in cancer therapy. *Acta Biochimica Polonica*, 51: 445-457.
12. Karam J., Benaim, E., Chen, H., Pong, R.C., Hsieh, J.T. (2005) Epigenetics in prostate cancer. *In Prostate Cancer: Mechanisms, Prevention, and Hormone Therapy* (Chang, C., ed), World Scientific, pp 213-228.
13. Zhang, Z., Karam, J., Frenkel, E.P., Sagalowsky, A., Hsieh, J.T. (2006) The Potential Application of Epigenetic Modifiers in the Treatment of Prostate and Bladder Cancer. *Urologic Oncol.*, 24:152-160.
14. Hsieh, J.T., Karam, J.A., Min, W. (2007) The Link of Genetic and Biologic Evidence from DAB2IP gene with Aggressive Prostate Cancer. *JNCI*, 99:1823-1824.
15. Hsieh, J.T. (2007) Translation from Basic Research to Therapeutic Exploration on Prostate Cancer. *J. Geriatrics & Health Care*, 13:131-137.

16. Karam, J. A., Shariat, S.F., Hsieh, J.T., Knowles, M.A. (2008) Genomics- preview of genomic medicine. *BJU* 102: 1221-1227.
17. Karam, J. A., Hsieh, J.T. (2009) Anti-cancer strategy of transitional cell carcinoma of bladder based on induction of different types of programmed cell deaths. *Apoptosis in Carcinogenesis and Chemotherapy* (Chen, GC, ed.) Springer, pp 25-50.
18. Hsieh, J.T., Wu, K., Yang, L. Zhou, J., He, D. (2010) Mechanisms leading to the development of androgen-independent prostate cancer. *J. Modern Urol.*, 6:401-407.
19. Yun, E., Wu, K., Tsai Y-S., Xie, D., Hsieh, J.T. (2013) The functional role of DAB2IP, a homeostatic factor, in prostate cancer. In *Prostate Cancer: Biochemistry, Molecular Biology and Genetics*, (Tindall, D, ed.) Springer, pp275-293.
20. Lo, S., Kumar, A., Hsieh, J.T., Sun, X. (2013) Dendrimer nanoscaffolds for potential theranostics in prostate cancer. *Mol. Pharm.*, 10:793-812.
21. Lo, U., Yang, D., Hsieh, J.T. (2013) The role of microRNAs in prostate cancer progression. *Trans. Androl. Urol.*, 2: 228-241.
22. Liu, H.H., Tsai, Y.S., Lai, C.L., Tang, C.H., Lai, C.H., Wu, H.C., Hsieh, J.T., Yang C.R. (2014) Evolving avenue of personalized therapy for castration-resistant prostate cancer. *BioMed.*, 4:e7-15.
23. Yun, E., Hsieh, J.T. (2014) Cancer stem cell in castration-resistant prostate cancer: altering the adaption landscape with new therapeutic implication. *Adaptive Med.*, 6: 6-11.
24. Lin, C.J., Lai, C.K., Kao, M.C., Wu, L.T., Lo, U-G., Lin, L.C., Chen, Y.A., Lin, H., Hsieh, J.T., Lai, C.H., Li, C.D. (2015) Impact of cholesterol on disease progression. *BioMedicine*, 5:1-7.

### C. Abstracts

1. Verma, A.K., Pong, R.C., Erickson, D., Hsieh, J.T. (1986) Protein kinase C and skin tumor promotion: calcium regulation of induction of ornithine decarboxylase (ODC) in primary culture of newborn mouse epidermal cells (MEC) by 12-*O*-tetradecanoylphorbol-13-acetate (TPA). *Proc. Am. Assoc. Cancer Res.*, 27, 147.
2. Hsieh, J.T., Verma, A.K. (1986) The role of protein kinase (PKC) in ornithine decarboxylase (ODC)-gene expression by 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in the T24 human bladder carcinoma cells. *FASEB J.*, 45, 1585.
3. Hsieh, J.T., Verma, A.K. (1987) Involvement of protein kinase C (PKC) in the transcriptional regulation of ornithine decarboxylase (ODC)-gene expression by 12-*O*-tetradecanoyl-phorbol-13-acetate (TPA) in the T24 human bladder carcinoma cells. *Proc. Am. Assoc. Cancer Res.*, 28, 10.

4. Hsieh, J.T., Verma A.K. (1987) Lack of the role of DNA methylation in tumor promoter phorbol ester-induced ornithine decarboxylase (ODC) gene transcription in the T24 human bladder carcinoma cells. In Polyamines Gordon Research Conference, Colby-Sawyer College, Laconia, NH, July 6-10.
5. Pong, R.C., Hsieh, J.T., Denning, M.F., Verma, A.K. (1988) Protein kinase C-mediated phosphorylation of 37 and 40 kd polypeptides and increased transcription of the ornithine decarboxylase gene in the T24 human bladder carcinoma cells. Proc. Am. Assoc. Cancer Res., 29, A308.
6. Mehta, M., Kubsad, S.S., Verma, A., Hsieh, J., Kinsella, T. (1988) An *in vivo* model for dosimetric analysis of radio-labeled monoclonal antibodies. Proc. Am. Assoc. Cancer Res., 29, 429.
7. Hsieh, J.T., Verma, A.K. (1989) Molecular cloning of human ornithine decarboxylase gene from chromosome 2 library. Proc. Am. Assoc. Cancer Res., 30, A1813.
8. Hsieh, J.T., Zhau, H.Y.E., Hong, S.J., Chung, L.W.K. (1990) Mesenchymal-mediated androgen responsiveness of human epithelial tumor growth *in vivo*. FASEB. J., 4, A486.
9. Gleave, M.E., Hsieh, J.T., Maringo, S.R., Chung, L.W.K. (1991) A novel animal model for the evaluation of factors affecting prostate specific antigen levels. J. Urol., 145, 402A.
10. Gleave, M.E., Hsieh, J.T., von Eschenbach, A.C., Chung, L.W.K. (1991) Prostate and bone fibroblasts induce human prostate carcinoma growth *in vivo* : implications for bidirectional stromal-epithelial interaction in prostate carcinoma growth and metastases. J. Urol., 145, 213A. **Note: This abstract won First-Prize of AUA essay contest.**
11. Zhau, H.Y.E., Wan, D., Chung, L.W.K., Li, W., Hsieh, J.T., Ro, J., Chung, L.W.K. (1991) Expression of the *her-2/neu* protooncogene in human prostate cancer. J. Urol., 145, 348A.
12. Chung, L.W.K., Gleave, M.E., Hsieh, J.T., Zhau, H.Y.E. (1991) Stromal-epithelial interaction in prostate tumor growth and progression. FASEB. J., 5, A1260.
13. Hsieh, J.T., Gleave, M.E., Li, W., Zhau, H.Y.E., von Eschenbach, A.C., Chung, L. W. K. (1991) Paracrine mediated acceleration of human bladder cancer growth: roles of growth factors and extracellular matrix. J. Urol., 145, 228A.
14. Hsieh, J.T., Wang, X.H., Zhau, H.Y.E., Liew, C.C., Chung, L.W.K. (1991) Cloning and characterization of a specific cytokeratin subtype cDNA clone from the rat ventral prostate gland (VP): Evidence for a new class of androgen-repressed gene. J. Urol., 145, 330A.
15. Hsieh, J.T., Wang, X.H., Zhau, H.Y.E., Chung, L.W.K. (1991) Regulation of cytokeratin expression in rat and human prostate: evidence for androgen repression in normal prostate and loss of pairwise control in prostatic cancer cell lines. Proc. Am. Assoc. Cancer Res., 32, 213.

16. Hsieh, J.T., Zhau, H.Y.E., Wang, X-H., Wan, D., Zhou, J-X., Chung, L.W.K. (1991) Coordinated repression of cytokeratin gene expression by androgen in rat accessory sex organs. In The Society for Basic Urology Research (SBUR) Annual Meeting, Toronto, Ontario, Canada, June 1.
17. Hsieh, J.T., Wang, X.H., Chung, L.W.K. (1991) Differential localization of luminal-specific cytokeratin gene expression in the rat prostatic epithelium during postnatal development. In The Society for Basic Urology Research (SBUR) Fall Symposium, Mayo Clinic, Rochester, MN, November 22-25.
18. Li, W., Song, Y., Hsieh, J.T., Hoosein, N. (1991) The role of androgen and adrenergic b<sub>2</sub>-receptor pathways in prostatic functional differentiation. In The Society for Basic Urology Research (SBUR) Fall Symposium, Mayo Clinic, Rochester, MN, November 22-25.
19. Hsieh, J.T., Gleave, M., Wu, H-C., Wang, X.H., Chung, L.W.K. (1992) Deranged control of androgen-regulated genes in the relapse stage of human prostatic cancer after castration: Implication for the derivation of androgen-independent cells by adaptive mechanism. *J. Urol.*, 147, 414A.
20. Pisters, L.L., Hsieh, J.T., Wang, X-H., Zhau, H.E., Bandyk, M.G., von Eschenbach, A.C., Chung, L.W.K. (1992) The relationship between androgen and differential expression of c-erb B2/Neu (Neu), epidermal growth factor receptor (EGFR), cytokeratin 8 (CK 8), and the prostate-binding protein gene (C-3) by rat ventral prostate (RVP) during postnatal development. *J. Urol.*, 147, 318A.
21. Wu, H-C., Hsieh, J.T., Gleave, M.G., Sikes, R., Logothetis, C., Chung, L.W.K. (1992) Combination therapy with transforming growth factor a-Pseudomonas exotoxin fusion protein (TP40) and retinoic acid in human bladder transitional cell carcinoma cell lines. *J. Urol.*, 147, 404A.
22. Gleave, M.G., Hsieh, J.T., Wu, H-C., von Eschenbach, A.C., Chung, L.W.K. (1992) Evaluation of the pharmacokinetics of PSA using the LNCaP tumor model. *J. Urol.*, 147, 386A.
23. Hsieh, J.T., Wu, H-C., Li, W., Gao, C., Chung, L.W.K. (1992) Human bone fibroblasts promote the progression of human prostate cancer. 6th Prouts Meeting on Prostate Cancer, Maine, October 15-18.
24. Hsieh, J.T., Wu, H-C., Gleave, M.E., Chung, L.W.K. (1992) Molecular analysis of tumor progression in a new model of human prostate cancer. In The Society for Basic Urology Research (SBUR) Fall Symposium, University of Washington, St. Louis, MO, October 3-6.
25. Pisters, L.L., Hsieh, J.T., Bandyk, M.G., Zhau, H.E., Johnson, D.E. (1992) The molecular analysis of extracellular matrix associated gene expression in mouse skin treated with an 830 nm low power laser. pp. 171-174. In 3rd World Congress International Society of Low power Laser Applications in Medicine, Bologna, Italy, Sept. 9-12.

26. Hsieh, J.T., Wu, H-C., Li, W., Logothetis, C., Chung, L.W.K. (1993) Detection of a non-androgen PSA-inducing protein factor(s) in bone marrow aspirates of patients with androgen-refractory prostate tumors : A potential prognostic marker(s) for disease progression. *J. Urol.*, 149, 257A.
27. Hsieh, J.T., Wu, H-C., Logothetis, C., von Eschenbach, A.C (1993) Characterization of non-androgenic prostate-specific autocrine factor(s) with stimulatory effect on PSA gene expression in androgen-independent human prostate cancer cells. *J. Urol.*, 149, 222A.
28. McDonnell, T.J., Troncoso, P., Brisbay, S.M., Logothetis, C., Chung L.W.K., Hsieh, J.T., Tu, S-M., Campbell, M.L (1993) BCL-2 expression in androgen-independent prostate carcinoma. *J. Urol.*, 149, 221A.
29. Wu, H-C., Hsieh, J.T., Chung, L.W.K., von Eschenbach, A.C (1993) Cellular interaction between prostate cancer and bone leading to androgen-independent cancer progression. *J. Urol.*, 149, 425A. **Note: This abstract won Third-Prize of AUA essay contest.**
30. Pisters, L.L., Troncoso, P., Zhau, H.E., Gao, C., Bandyk, M.G., Hsieh, J.T., Li, W., Rubin, J.S., Chung, L.W.K., and von Eschenbach, A.C (1993) The role of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the c-met proto-oncogene in human prostatic tumor growth. *J. Urol.*, 149, 482A.
31. Hsieh, J.T., Wu, H-C., Anezinis, P., Chang S.M., Chung, L.W.K., (1993) An androgen-independent model of human prostate cancer progression: molecular and cellular characterization. *Proc. Am. Assoc. Cancer Res.*, 34, 248.
32. Anezinis, P., Chang S.M., Hsieh, J.T., Chung, L.W.K., (1993) Effect of autocrine growth factor(s) produced by androgen-independent LNCaP sublines. In *The Society for Basic Urology Research (SBUR) Annual Meeting, San Antonio, Texas, May 15.*
33. Hsieh, J.T., Lin S-H., (1993) Androgen-regulated cellular adhesion molecule (C-CAM105) during rat ventral prostate degeneration. In *The Society for Basic Urology Research (SBUR) Annual Meeting, San Antonio, Texas, May 15.*
34. Hsieh, J.T., Luo, W., Song, W., Kleinerman, D., Van, N.T., Wang, Y., Lin S-H., (1994) Suppression of tumorigenicity of human prostate carcinoma cells by expression of an androgen-regulated epithelial cell adhesion molecule (C-CAM). *J. Urol.*, 151, 369A.
35. Kleinerman, D., Troncoso, P., Brooks, T., von Eschenbach, A.C., Lin S-H., Hsieh, J.T., (1994) The expression of an epithelial cell adhesion molecule (C-CAM) in human prostate development and in prostate carcinoma. *J. Urol.*, 151, 251A.
36. Hsieh, J.T., Kleinerman, D., Troncoso, P., Lin S-H. (1995) C-CAM, an epithelial-specific cell adhesion molecule, as a tumor suppressor in prostate cancer: the homeostatic role of C-CAM in prostate epithelial regeneration. *J. Urol.*, 153, 447A.



37. Kleinerman, D., von Eschenbach, A.C., Lin S-H., Hsieh, J.T. (1995) C-CAM as a tumor suppressor in human prostate carcinoma: a potential candidate for gene therapy. *J. Urol.*, 153, 306A. **Note: This abstract won Second-Prize of AUA essay contest.**
38. Kleinerman, D., Hsieh, J.T., Colin, P.N.D. (1995) The tumor suppressive role of an epithelial cell-specific adhesion molecule (C-CAM) in human bladder cancer progression. *J. Urol.*, 153, 522A.
39. Gotoh, A., Ko, A.S.C., Kao, C, Ho, L.J., Hsieh, J.T., Chung, L.W.K. (1995) New strategy of toxic gene therapy for human prostate cancer cells. *J. Urol.*, 153, 308A.
40. Kleinerman, D., Troncoso, P., Pisters, L., Navone, N.M., Hsieh, J.T., Logothetis, C.J., von Eschenbach, A.C., Sleddens, H. F.B.M., van der Kwast, T.H., Brinkman, A.O., Schroder, F.H., Trapman, J. (1996) Expression and structure of androgen receptor in bone metastases of hormone refractory prostate cancer. *J. Urol.*, 155, 522A.
41. Chen, B., Hall, C.M., Pong, R.C., Li, Y., Sagalowky, A., Hsieh, J.T. (1997) The application of a novel tumor suppressor gene (C-CAM1) in human bladder cancer gene therapy. *J. Urol.*, 157, 307A
42. Hsieh, J.T., Pong, R.C., Early K, Wang, Y., Li, Y., Lin S-H. (1997) Analysis of tumor suppressive function of C-CAM1 molecule in prostate cancer cells. *Proc. Am. Assoc. Cancer Res.*, 38, 81.
43. He, D.L., Mu, Z-M., Le, X., Hsieh, J.T., Chung, L.W.K., Chang, K-S. (1997) Growth inhibition of prostate and breast cancer cells by the PML tumor suppressor gene mediated by adenovirus vector. *Proc. Am. Assoc. Cancer Res.*, 38, 11.
44. Tseng, C-P., Ely, B., Pong, R. C., Ma, C. R., Hsieh, J.T.(1998) Characterization of a putative homeostatic signaling protein C9 in prostate development. *Proc. Am. Assoc. Cancer Res.*, 39, 201.
45. Tseng, C-P., Pong, R.C., Li, Y., Ely, B., Hsieh, J.T.(1998) The suppressive function and regulation of C9, a putative adaptor protein of cellular signaling, in human prostate cancer. *Proc. Am. Assoc. Cancer Res.*, 39, 654.
46. Tseng, C-P., Ely, B., Pong, R.C., Li, Y., Hsieh, J.T.(1998) Characterization of a novel signal molecule in prostate development and prostate cancer progression. *J. Urol.*, 159, 4A.
47. Hall, M.C., Li, Y., Ely, B., Sagalowsky, A.I., Hsieh, J.T. (1998) Function role of p21 (WAF-1/CIP-1) in human bladder cancer progression and potential gene therapy application. *J. Urol.*, 159, 280A.
48. Li Y., Pong, R.C., Hall, M.C., Tseng, C-P., Wang, Z., Sagalowsky, A.I., Bergelson, J.M., Hsieh, J.T. (1999) Differential expression of coxsackie and adenovirus receptor (CAR) in human bladder cancer cells- a potential impact on the efficiency of gene therapy. *Proc. Am. Assoc. Cancer Res.*, 40, 476.

49. Hsieh, J.T., Tseng, C.P., Wang, Z., Pong, R.C., Ely, B. (1999) An underlying mechanism of DOC-2 in inhibiting AP-1 activity. *Proc. Am. Assoc. Cancer Res.*, 40, 516.
50. Tseng, C.P., Wang, Z., Pong, R.C., Li, Y., Ely, B., Hsieh, J.T. (1999) An underlying mechanism of tumor suppressor gene, DOC-2, in prostate cancer. *J. Urol.*, 160, 60A.
51. Pong, R.C., Li, Y., Hall, M.C., Tseng, C-P., Wang, Z., Sagalowsky A.I., Hsieh, J.T. (1999) Loss of adenoviral receptor expression in human bladder cancer cells- a potential impact on the efficacy of gene therapy. *J. Urol.*, 160, 112A.
52. Leach, F.S., Hsieh, J.T., McConnell, J.D., Sagalowsky A.I. (1999) Increased expression of the human mismatch repair gene, *hMSH2*: a useful marker for detection of genitourinary cancer. *J. Urol.*, 160, 112A.
53. Wang, Z., Tseng, C-P., Pong, R.C., Li, Y., Hsieh, J.T. (1999) Characterization of a novel member of Ras-GAP gene family in prostate cancer. *J. Urol.*, 160, 128A.
54. Okegawa, T., Li, Y., Pong, R.C., Hsieh, J.T. (2000) Mechanism of coxsackie and adenovirus receptor (CAR) and its impact on prostate cancer therapy. *Proc. Am. Assoc. Cancer Res.*, 41, 351.
55. Martinez, L.A., Sikes, R.C., J.T. Hsieh, Navone, N.M. (2000) Role of p21 WAF1/CIP1 in prostate cancer drug resistance. *Proc. Am. Assoc. Cancer Res.*, 41, 251.
56. Wang, Z., Tseng, C-P., Pong, R.C., Sherif, H., Hsieh, J.T. (2000) A novel signaling pathway in prostate development and cancer progression. *J. Urol.*, 163, 30A.
57. Okegawa, T., Pong, R.C., Li, Y., Bergelson, J., Sagalowsky A.I., Hsieh, J.T. (2001) A unique application of coxsackie and adenovirus receptor (CAR) on human bladder cancer therapy. *J. Urol.*, 165, 112A.
58. Maruyama, R., Toyooka, S., McConnell, J.D., Hsieh, J.T., Frenkel, E.P., Gazdar, A.F. (2001) Aberrant promoter methylation profile of prostate cancers and its relationship to clinical findings. *J. Urol.*, 165, 112A.
59. Okegawa, T., Pong, R.C., Li, Y., Bergelson, J., Saboorian, H., Sagalowsky, A.I., Hsieh, J.T. (2001) The mechanism of action of coxsackie and adenovirus receptor and its application in human bladder cancer. *International Bladder Symposium*, Washington, D.C., March 8-11.
60. Pong, R.C., Li, Y., Okegawa, T., Saboorian, H., Lindberg, G., Sagalowsky, A., Hsieh, J.T. (2002) Evaluating the Expression of the Coxsackie and Adenovirus Receptor (CAR) in Patients with Bladder Cancer. *J. Urol.*, 167, 111A.
61. Li, Y., Baseman, A.G., Elmore, J., Wilhelm, D.A., Kacka, M., Hsieh, J.T., Koeneman, K.S. (2002) Bone sialoprotein conditionally replication competent adenoviral treatment of bladder cancer: correlation to BSP, CAR and GR expression. *J. Urol.*, 167, 116A.

62. Hsieh, J.T., Pong, R.C., Li, Y., Saboorian, H., Sagalowsky, A.I., (2003) The inhibition of cyclooxygenase-2 (COX-2) expression by Coxsackie and adenovirus receptor (CAR) in bladder cancer. *J. Urol.*, 169, 186A.
63. Okegawa, T., Horie, S., Nutahara, K., Higashihara, E., Hsieh, J.T. (2003) The histone deacetylase inhibitor FR901228 preferentially enhances adenovirus transgene expression in bladder cancer. *J. Urol.*, 169, 188A.
64. Lin, V.K., Barbero, G., Lin, C., Wang, S., Sayne, J., Hsieh, J.T., McConnell, J.D., Roehrborn, C.G. (2003) Distribution of 5- $\alpha$  reductase isoenzymes types 1/2 and DOC-2/DAB2 in BPH. *J. Urol.*, 284A.
65. Chen, H., Toyooka, S., Gazdar, A.F., Hsieh, J.T. (2003) Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. *Proc. Am. Assoc. Cancer Res.*, 44, 325.
66. Zhou, J., Scholes, J., Hernandez, G., Hsieh, J.T. (2003) A new inhibitory mechanism of c-Src by DOC-2/DAB2 in prostate cancer. *Proc. Am. Assoc. Cancer Res.*, 44, 998.
67. Dote, H., Toyooka, S., Tsukuda, K., Yano, M., Taira, N., Shien, T., Ota, T., Naito, M., Murakami, M., Doihara, H., Chen, H., Hsieh, J.T., Gazdar, A.F., Shimizu, N. (2003) Aberrant methylation and expression status of human DAB2 interactive protein (hDAB2IP) in breast cancers. *Proc. Am. Assoc. Cancer Res.*, 44, 255.
68. Pong, R.C., Roark, R., Frenkel, E.P., Sagalowsky, A.I., Hsieh, J.T. (2004) Synergistic induction of coxsackie and adenovirus receptor by histone deacetylase and Ipriflavone in human bladder cancer cells. *Proc. Am. Assoc. Cancer Res.*, 45, 271.
69. Karam, J.A., Benaim, E.A., Frenkel, E.P., Hsieh, J.T. (2004) 5-Azacytidine and Depsipeptide control the growth of bladder cancer, *in vitro* and *in vivo*. *Proc. Am. Assoc. Cancer Res.*, 45, 369.
70. Zhou, J., Hernandez, G., Hsieh, J.T. (2004) The inhibitory effect of a tumor suppressor (DOC-2/DAB2) on androgen receptor-mediated non-genomic signal pathway in prostate cancer. *Proc. Am. Assoc. Cancer Res.*, 45, 618.
71. Hsieh, J.T., Pong, R.C., Roark, R., Frenkel, E.P., Sagalowsky, A.I. (2004) Upregulation of coxsackie and adenovirus gene expression by novel chemotherapeutic agents in bladder cancers. *J. Urol.*, 171, 254.
72. Karam, J.A., Benaim, E.A., Frenkel, E.P., Hsieh, J.T. (2004) New therapeutic regimen for transitional cell carcinoma targeting the epigenetic gene regulatory machinery. *J. Urol.*, 171, 255.
73. Ren, G., Pong, R., Xie, D., Hsieh, J.T., Öz, O.K. (2004) "*In vivo imaging of gene therapy*". *Mol. Imaging and Biology*, 6: p. 82.

74. Ren, G., Qurashi, M., Kulkarni, P., Mason, R.P., Parkey, R.W., Hsieh, J.T., Öz, O.K. (2005) Molecular imaging guided urogenital cancer therapy. *J Nucl. Med.*, 46,Supple 2:199.
75. Ren, G., Qurashi, M., Kulkarni, P., Parkey, R.W., Hsieh, J.T., Öz, O.K. (2005) Targeted imaging in urogenital cancer. *Mol. Imaging*, 4:284-285.
76. Zhang, Z., Stanfield, J., Frenkel, E.P., Hsieh, J.T. (2005) Histone deacetylase inhibitor FK228 enhances therapeutic efficacy of docetaxel in human androgen independent prostate cancer. *Am. Assoc. Cancer Res.*, (Abstract# LB-245) **Note: This abstract was chosen in Late-Breaking poster section.**
77. Chen, H., Hsieh, J.T. (2005) Silencing of human DAB2IP gene expression mediated by polycomb Ezh2 complex in prostate cancer. *Am. Assoc. Cancer Res.* (Abstract# LB-245)
78. Zhou, J., Hernandez, G., Scholes, J., Chen, H., and Hsieh, J.T. (2005) Cooperative effect of interaction between histone acetylation and GATA transcription factor on a tumor suppressor (DOC-2/DAB2) gene expression in bladder cancer cells. *Am. Assoc. Cancer Res.*, 46, 718.
79. Okegawa, T., Nutahara, K., Hsieh, J.T., and Higashihara, E., (2005) Evaluation of coxsackie and adenovirus receptor in patients with renal cell carcinoma. *J. Urol.*, 173, 105.
80. Roark, R., Pong, R.C., Collins, W., Hsieh, J.T. (2005) Effect of natural compound on the expression of coxsackie and adenovirus gene expression in transitional cell carcinoma. *J. Urol.*, 173, 210.
81. Zhang, Z., Stanfield, J., Hsieh, J.T. (2006) The potential application of histone deacetylase inhibitor on androgen independent prostate cancer. *J. Urol.*, 175: 90.
82. Walsh, L., Cho, L.C., Khaled, F.A., Chang, C.H., Forster, K., Kabrani, W., Cadeddu, J.A., Hsieh, J.T., Choy, H., Timmerman, R., Lotan, Y. (2006) Efficacy of ablative high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. *J. Urol.*, 175: 131.
83. Okegawa, T., Nutahara, K., Higashihara, E., Pong, R.C., Hsieh, J.T. (2006) Enhanced transgene expression in urothelial cancer gene therapy with tranilast. *J. Urol.*, 175: 201.
84. Walsh, L., Miller, M.R., Anderson, J.K., Han, B., Hsieh, J.T., Lotan, Y., Cadeddu, J.A. (2006) In vitro assessment of the efficacy of thermal therapy in human renal cell carcinoma. *J. Urol.*, 175: 352.
85. Shariat S.F., Margullis, V., Ashfaq, R., Thompson, M., Sagalowsky, A., Hsieh, J.T. (2006) Correlation of cyclooxygenase-2 expression with molecular marker, pathologic features, and clinical outcome of transitional cell carcinoma of urinary bladder. *J. Urol.*, 175: 402.

86. Fan, Jinahai, Roark, R., Pong, R.C., Hsieh, J.T. (2006) Enhancing the inductivity of depsiptide (FK228) on adenovirus receptor and its therapeutic efficacy on the treatment of human bladder cancer by Tranilast and its analogue. *Am. Assoc. Cancer Res. (Abstract#5452)*.
87. Zhou, J., Zhang, Z., Stanfield, J., Fan, J., Hsieh, J.T. (2006) A new strategy for prostate cancer with a small molecular therapy. *Am. Assoc. Cancer Res. (Abstract#2183)*.
88. Stern, J.M., Hsieh, J.T., Park, S., Lotan, Y., Cadeddu, J.A. (2007) Successful gold nanoshell assisted laser ablation of prostate carcinoma in vitro. *J. Urol.*, 177: 52.
89. Stern, J.M., Stanfield, J., Hsieh, J.T., Cadeddu, J.A. (2007) Novel laser activated gold nanoshell thermal ablation of human prostate cancer in vivo. *J. Urol.*, 177: 210.
90. Huang, H-Y., Shariat, S.F., Sun, T-T., Lepor, H., Shapiro, E., Hsieh, J.T., Ashfaq, R., Lotan, Y., Wu, X-R. (2007) Persistent uroplakin expression in advanced urothelial carcinoma: implications in clinical outcome. *J. Urol.* 177: 296.
91. Karam, J.A., Shariat, S.F., Ashfaq, R., Huang, H-Y., Shapiro, E., Lotan, Y., Sagalowsky, A.I., Wu, X-R., Hsieh, J.T. (2007) Loss of DOC-2/DAB2 expression is associated with aggressive features of bladder cancer. *J. Urol.* 177: 548.
92. Hsieh, J.T., Huang, S., Fan, J., Pong, R.C., Sagalowsky, A.I. (2008) Upregulation of TRAG3 gene, a surrogate marker for docetaxel resistance, associated with aggressive bladder cancer. *J. Urol.* 179
93. Xie, D., Hsieh, J.T. (2008) The functional study of DAB2IP in prostate cancer- a new marker associated with risk of aggressive tumor. *J. Urol.* 179:389.
94. Xie, D., Hsieh, J.T. (2009) The impact of DAB2IP on epithelial-mesenchymal transition (EMT) leading to prostate cancer metastasis. *Am. Assoc. Cancer Res. (Abstract#2183)*.
95. Zhou, J., Gore, C., Hsieh, J.T., Zimmermann P (2009) Developing bladder specific targeting agent using cell permeable peptide. *J. Urol.* 181.
96. Yang, L., Ravindranathan, P., Hsieh, J.T., Raj, G. (2010) Evidence for a central role for PELP-1 in androgen receptor mediated genomic signaling in prostate cancer. *J. Urol.* 183, e498.
97. Wu, K., Xie, D., Gore, C., Tseng, S.F., He, D., Hsieh, J.T. (2011) DAB2IP as a potent inhibitor of androgen receptor hyperactivation in prostate cancer via several mechanisms of actions. *J. Urol.* 185, e1447.
98. Yang, L., Ravindranathan, P., Hsieh, J.T., Raj, G. (2011) Early induction of epithelial-to-mesenchymal transition following androgen deprivation in prostate cancer cells is snail-dependent. *J. Urol.* 185, e1458.

99. Wu, K., Zhou, Y., Zhang, T.T., Gleave, M., He, D., Boothman, D., Hsieh, J.T. (2012) Mechanism of chemo-resistance in prostate cancer cells via DAB2IP-Clusterin signaling pathway. AUA annual meeting.
100. Wu, K., Gore, C., Yang, L., Gleave, M., Pong, R.C., Hsieh, J.T., He, D. (2012) Reciprocal regulation of Slug and androgen receptor facilitates prostate cancer to acquire castration resistant and stem-like phenotypes. AUA annual meeting.
101. Lo, U., Pong, R.C., Tseng, S.F., Hsieh, J.T. (2013) MicroRNA-363 regulated by a novel tumor suppressor suppresses epithelial-to-mesenchymal transition in prostate cancer. AUA annual meeting (#199).
102. Wu, K., Ning, Z., Pong, R.C., Hsieh, J.T., He, D. (2013) Prostate Cancer Cell with Loss of DAB2IP acquires survival advantage after androgen deprivation through STAT3/Survivin activation. AUA annual meeting (#202).
103. Zhou, J., Wu, K., Kapur, P., Pong, R.C., Zhu, G., He, D., Hsieh, J.T. (2013) Correlation of loss of DAB2IP gene expression with different subtypes of renal cell carcinoma and its mechanism of action. AUA annual meeting (#300).
104. Ilyas, A., Ali, W., Hsieh, J.T., Lotan, Y., Kim, Y., Iqbal S.M. (2014) Tagless Discrimination And Detection Of Cancer Cells Using Solid-State Micropores. BMES 2014 Annual Meeting (#226).
105. Pandey, N., Wadajkar, A.S., Sundaresan, V., Hernandez, E., Hsieh, J.T., Tang, L., Yang, J., Nguyen, K.T. (2014) Thermo-responsive, Multimodal Imaging Enabled Nanoparticles Towards Cancer Therapy. BMES 2014 Annual Meeting (#1049).
106. Lo, U., Pong, R.C., Yang, D., Gandee, L., Zhou, J.C., Tseng, S-F., Hsieh, J.T. (2015) Identification of a new mechanism of microRNA turnover from miR-106a-363 cluster leading to epithelial-to-mesenchymal transition in prostate cancer. AACR annual meeting.

#### CURRENT GRANT SUPPORT

1. Army/Department of Defense, Principal Investigator, "Role of microRNA in aggressive prostate cancer" 450,000/2011-2015.
2. Army/Department of Defense, Co-Principal Investigator, "Enhancement of radiation therapy in prostate cancer by DNA-PKcs inhibitor", \$450,000/2011-2014.
3. National Institutes of Health, Principal Investigator, "Targeting aggressive prostate cancer with novel theranostic nanomedicine ", \$1,000,000/2011-2016.
4. Army/Department of Defense, Co-Principal Investigator, "Molecular innovations towards theranostics of aggressive prostate cancer", \$750,000/2012-2015.
5. CPRIT, Co-Principal Investigator, "Cancer treatment, including drug discovery/development, and clinical trials", \$6,627,179/2012-2017.
6. National Institutes of Health, Principal Investigator, "Developing targeted therapy with prostate cancer specific nanomedicine", \$1,250,000/2013-2018.

7. National Institutes of Health, Co-Principal Investigator, "Role of DAB2IP in Prostate Cancer Patients Treated with Radiation Therapy", \$270,000/2014-2016.
8. National Institutes of Health, Co-Principal Investigator, "Surface Chemistry for High-contrast Fluorescent Kidney imaging", \$800,000/2014-2018.
9. CPRIT, Co-Principal Investigator, "Mapping Acidic Tumor Microenvironment with Renal Clearable pH Nanoindicators", \$900,000/2014-2017.

#### PENDING GRANT

1. National Institutes of Health, Principal Investigator, "Targeting renal cancer stem cell", \$275,000/2015-2017.
2. National Institutes of Health, Principal Investigator, "Mechanism of Specific microRNA turnover from a gene cluster leading to epithelial-to-mesenchymal transition", \$275,000/2015-2017.
3. National Institutes of Health, Co-Principal Investigator, "LR-targeted NPs to Treat Docetaxel Resistant Metastatic Prostate Cancer", \$275,000/2015-2017.
4. National Institutes of Health, Co-Principal Investigator, "Targeting a new kind of photosensitizer nanoparticles on prostate cancer treatment", \$1,250,000/2015-2020.

#### PATENT

1. Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis (US: 5,728,815).
2. Imaging and therapeutic targeting of prostate and bladder tissues (US: 7,919,579).

#### TEACHING EXPERIENCE

1995	Molecular Progression of Prostate Cancer Course for Postdoctoral fellow and Residents from Urology and Genitourinary Oncology
1995	Molecular techniques for graduate student
1998	Molecular biology of urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
1999	Principles of Molecular Genetics for urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
2001	Principles of Molecular Genetics in urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
2003	Principles of Molecular Genetics in urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
2005	Principles of Molecular Genetics in urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
2007	Epigenetic regulation in stem cell and malignant cell for graduate students
2007	Molecular biology of urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
2008	Cancer Biology I – “Stem Cells, Cancer and Cancer Stem Cells”, Cancer Biology Training Program, UT Southwestern

2008	Molecular biology of urologic diseases for Clinical fellow and Residents, Department of Urology, UT Southwestern
2009	Cancer Biology I – “Stem Cells, Cancer and Cancer Stem Cells” Cancer Biology Training Program, UT Southwestern
2009	Cancer Biology, Bioengineering Training Program, UT-Arlington
2010	Cancer Biology II – “Stem Cells, Cancer and Cancer Stem Cells” Cancer Biology Training Program, UT Southwestern
2010-2014	Biotechnology in Cancer Biology, Graduate Institute of Cancer Biology, China Medical University, Taiwan

UNDERGRADUATE, GRADUATE AND POSTGRADUATE STUDENTS ADVISED

1993-1995	David Kleinerman, M.D. (Clinical Fellow)
1993-1995	Philip Philip, M.D. (Clinical Fellow)
1993-1995	Weitao Song, Ph.D. (Post-doctoral Fellow)
1993-1995	Yan Wang, M.D. (Post-doctoral Fellow)
1995-1995	Gary Engstrom, M.D. (Clinical Fellow)
1995-1995	Ian Chiu (Summer student)
1995-1995	Xiaopeng Liu (Summer student)
1995-1996	Bing Jiang, Ph.D. (Post-doctoral Fellow)
1995-1996	Bo-qui Chen, M.D. (Clinical Fellow)
1996-1996	Charles Cobb, M.D. (Resident)
1996-1997	Fred Leach, M.D. (Resident)
1996-1997	Congrong Ma, Ph.D. (Post-doctoral Fellow)
1997-1997	Eric Smith (Medical student)
1996-1998	Brent Ely (Undergraduate student)
1996-1998	Ching-Ping Tseng, Ph.D. (Post-doctoral Fellow)
1998-1999	Tariq Khan (Undergraduate student)
1999-1999	Linya Yang (Undergraduate student)
1999-1999	Nazeer Khanani (Medical student)
1999-1999	Juan Montoya, M.D. (Resident)
1999-1999	Gwyndelon Harburg (Graduate student)
1999-1999	Michael Melkus (Graduate student)
1999-2000	Lisa Stevenson (Undergraduate student)
1995-2000	Yingming Li, M.D. (Post-doctoral Fellow)
2000-2000	Christopher Richardson (START student)
1998-2001	Zhi Wang, Ph.D. (Graduate student)
1999-2001	Takatsugu Okegawa, M.D. (Clinical Fellow)
2001-2003	Richard Hsu (SURF student)
2001-2002	Yun-Ju Lai, M.S. (Research fellow)
2000-2003	Oliver Hauss (Graduate student)
1999-2004	Jian Zhou, Ph.D. (Post-doctoral Fellow)
1999-2002	Hong Chen, M.S. (Research fellow)
2002-2003	DongHua Xie, M.D. (Clinical Fellow)
2003-2004	Jose Karam, M.D. (Clinical Fellow)



2003-2003	Wesley Wen (Summer student)
2003-2004	Ryan Roak (SURF student)
2003-2006	Zhengweng Zhang, M.D. (Post-doctoral Fellow)
2004-2004	Jessica Chu (START student)
2004-2007	Jinhai Fan, M.D. (Post-doctoral Fellow)
2005-2005	Kit Tam (SUMR student)
2007-2010	Daxing Xie, M.D., Ph.D. (Post-doctoral Fellow)
2007-2008	Sandra Huang, Ph.D. (Post-doctoral Fellow)
2007	Anand Tarpara (START student)
2009-2010	Stephen Chiang (SUMR student)
2009-2013	Shu-Fen Tseng (graduate student)
2009-2011	Kaijie Wu (graduate student)
2010-2011	Ting-Ting Zhang (graduate student)
2010-2013	Eunjin Yun, Ph.D. (Post-doctoral Fellow)
2010-2011	Yuh-Shyan Tsai, M.D., Ph.D. (Post-doctoral Fellow)
2011-2012	Lin-Lin Zhang, M.D., Ph.D. (Post-doctoral Fellow)
2011-present	U-ging Lo, Ph.D. (Post-doctoral Fellow)
2012-2014	Jiancheng Zhou (graduate student)
2012-2013	Hsin-ho Liu, M.D. (Clinical Fellow)
2012-2013	Chia-Yang Li, Ph.D. (Post-doctoral Fellow)
2012-2013	Yuefeng Du, M.D., Ph.D. (Post-doctoral Fellow)
2013-2014	Tao Wu (Clinical Fellow)
2013-2014	Jinhuan Wei (Clinical Fellow)
2014-2015	Heng-Wei Hsu (Post-doctoral Fellow)
2014-present	Bin Wang (graduate student)
2014-present	Wei Chen (graduate student)
2014-present	Grace Lin (graduate student)
2014-present	Cheng-Kuo Lai, Ph.D. (Post-doctoral Fellow)
2014-present	Joe Lin, Ph.D. (Post-doctoral Fellow)

#### STUDENT COMMITTEE

1997	Julie Wilsbacher (Ph.D., Cell Regulation)
1998	Jiantao Ding (Ph.D., Cell Regulation)
1999	Bih-Rong Wei (Ph.D., Immunology)
2000	Zhi Wang (Ph.D., Biochemistry)
2000	External Examiner for Simon Leung (M.D., Master of Surgery, Queen Mary Hospital, University of Hong Kong)
2002	Olive Hauss (M.S., Cell Regulation)
2003	Gang Ren (Ph.D., Radiology)
2005	Juang Yu-Chi (Ph.D., Cell Regulation)
2005	Evaul Kristen (Ph.D., Cell Regulation)
2005	Linlin Zhang (Ph.D., Xi'an Jiaotong University, Xi'an, China)
2007	Lingling Duan (Ph.D., Cell Regulation)
2008	Meredith Shidler (Ph.D., Cell Regulation)

2009 Wan-Chi Hsiao (M.S., Cancer Biology, China Medical University, Taiwan)

2009 Shiao-Chen Hung (M.S., Cancer Biology, China Medical University, Taiwan)

2009 Vanessa Damoulis (Ph.D., Cancer Biology)

2009 Samarpita Sengupta (Ph.D., Cell Regulation)

2009 Shu-Fen Tseng (Ph.D., Bioengineering)

2009 Cheng Yu Ko (Ph.D., Bioengineering)

2010 Aadil Kaisani (Ph.D., Cancer Biology)

2011 David Spence (M.S., Medical Technology, UNTHSC)

2011 Dustin Boyd (Ph.D., Cancer Biology)

2012 Marc Sprouse (Ph.D., Medical Technology, UNTHSC)

2012 Wing Cheng (Ph.D., Cancer Biology)

2012 Aniket Wadajkar (Ph.D., Bioengineering)

2012 Vikrant Sharma (Ph.D., Bioengineering)

2012 Su-Tang Lo (Ph.D., RadioBiology)

2012 Yi-Ting Tsai (Ph.D., Bioengineering)

2012 Nesreen Alsmadi (Ph.D., Bioengineering)

2013 Homa Homayoni (Ph.D., Bioengineering)

2014 Sayantan Maji (Ph.D., Molecular Biology and Immunology, UNTHSC)

## REFERENCES

1. Chawnshang Chang, Ph.D.  
Professor and Director  
George Whipple Lab for Cancer Research  
Department of Urology  
University of Rochester Medical Center  
601 Elmwood Ave., Box 626  
Rochester, NY 14642  
phone: (716) 275-9994
2. Donald S. Coffey, Ph.D.  
Professor  
Department of Urology  
John Hopkins Hospital  
Marburg 121  
600 N. Wolfe Street  
Baltimore, MD 21287-2101  
phone: (410) 955-2517
3. Martin E. Gleave, M.D.  
Professor  
Dept of Surgery (Urology)

Vancouver Hospital and Health Science Center  
2733 Heather Street, D-9  
Vancouver, B.C. Canada V5Z3J5  
phone: (604) 875-5003

4. Leland W.K. Chung, Ph.D.  
Professor and Director  
Molecular Urology and Therapeutic Program  
The Winship Cancer Center Institute  
Emory University Scholl of Medicine  
1365 Clifton Rd., NE, Suite 4100  
Atlanta, GA 30322  
phone: (404) 778-3672
5. [Natasha Kyprianou, M.D., Ph.D.](#)  
Professor and Director  
Urology Research laboratory  
Division of Urology  
University of Kentucky Medical Center  
800 Rose St, 306 Combs Bldg.  
Lexington, KY 40536  
phone: (859) 323-9812
6. Jonathan Simons, M.D.  
Professor  
The Winship Cancer Center Institute  
Emory University Scholl of Medicine  
1365 Clifton Rd., NE, Suite 4100  
Atlanta, GA 30322  
phone: (404) 778-5177
7. Robert L. Vessella, Ph.D.  
Professor and Director  
GU Cancer Research Laboratories  
Department of Urology  
University of Washington School of Medicine  
Box 356510  
Seattle, WA 98195-6510  
phone: (206) 543-3641
8. Chung Lee, Ph.D.  
Professor and Director  
Department of Urology  
Northwestern University School of Medicine  
Tarry Building 11-715

303 East Chicago Avenue  
Chicago, IL 60611-3009  
phone: (312) 908-2916

9. Andrew C. von Eschenbach, M.D.  
Acting Commissioner  
US Food and Drug Administration  
5600 Fishers Lane,  
Rockville MD 20857  
phone: (301) 827-2410
  
10. Ajit K. Verma, Ph.D.  
Professor  
Department of Human Oncology-K4/538  
CSC, 600 Highland Ave.,  
Madison, WI 53792  
phone: (608) 263-9136